Lixte Biotechnology (LIXT) 10-K 21 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 07, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'LIXTE BIOTECHNOLOGY HOLDINGS, INC.	'	'
Entity Central Index Key	'0001335105	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'LIXT	'	'
Entity Common Stock, Shares Outstanding	'	41,583,097	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$3,179,000

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
ASSETS	'	'
Cash	$475,019	$1,655,122
Money market funds	6,135	6,134
Advances on research and development contract services	33,880	51,575
Prepaid expenses and other current assets	43,006	40,179
Total current assets	558,040	1,753,010
Total assets	558,040	1,753,010
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable and accrued expenses	107,774	80,416
Research and development contract liabilities, including $34,398 and $9,679 to a related party at December 31, 2013 and 2012, respectively	47,283	14,019
Liquidated damages payable under registration rights agreement	74,000	74,000
Due to stockholder	92,717	92,717
Total current liabilities	321,774	261,152
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.0001 par value; authorized - 10,000,000 shares; issued - none	0	0
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 41,583,097 shares	4,158	4,158
Additional paid-in capital	13,184,081	13,064,831
Deficit accumulated during the development stage	-12,951,973	-11,577,131
Total stockholders' equity	236,266	1,491,858
Total liabilities and stockholders' equity	$558,040	$1,753,010

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Dec. 31, 2013	Dec. 31, 2012
Research And Development Contract Liabilities To Related Parties	$34,398	$9,679
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	41,583,097	41,583,097
Common stock, shares outstanding	41,583,097	41,583,097

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended		101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenues	$0	$0	$0
Costs and expenses:	'	'	'
General and administrative costs, including $115,768 and $724,204 to related parties for the years ended December 31, 2013 and 2012, respectively, and $2,763,909 for the period from August 9, 2005 to December 31, 2013 (cumulative).	494,959	1,093,614	5,727,899
Depreciation	0	0	1,909
Research and development costs, including $304,102 and $185,536 to related parties for the years ended December 31, 2013 and 2012, respectively, and $548,272 for the period from August 9, 2005 to December 31, 2013 (cumulative).	879,886	1,012,144	5,449,678
Reverse merger costs	0	0	50,000
Total costs and expenses	1,374,845	2,105,758	11,229,486
Loss from operations	-1,374,845	-2,105,758	-11,229,486
Interest income	3	8	27,437
Interest expense	0	0	-2,469
Fair value of warrant extensions	0	-1,139,592	-1,339,431
Fair value of warrant discount	0	-334,024	-334,024
Liquidated damages under registration rights agreement	0	0	-74,000
Net loss	($1,374,842)	($3,579,366)	($12,951,973)
Net loss per common share - Basic and diluted (per share)	($0.03)	($0.09)	'
Weighted average common shares outstanding - Basic and diluted (in shares)	41,583,097	38,985,832	'

CONSOLIDATED_STATEMENTS_OF_OPE1

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)	12 Months Ended		101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party	$115,768	$724,204	$2,763,909
Related Parties Research And Development Costs	$304,102	$185,536	$548,272

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $)	Total	Common Stock [Member]	Advances Under Equity Financing [Member]	Additional Paid-in Capital [Member]	Deficit Accumulated During the Development Stage
Balance at Aug. 08, 2005	$0	$0	$0	$0	$0
Balance (in shares) at Aug. 08, 2005	'	0	'	'	'
Shares issued to founding stockholder	1,500	1,902	0	-402	0
Shares issued to founding stockholder (in shares)	'	19,021,786	'	'	'
Net loss	-16,124	0	0	0	-16,124
Balance at Dec. 31, 2005	-14,624	1,902	0	-402	-16,124
Balance (in shares) at Dec. 31, 2005	'	19,021,786	'	'	'
Shares issued in connection with reverse merger transaction	62,500	401	0	62,099	0
Shares issued in connection with reverse merger transaction (in shares)	'	4,005,177	'	'	'
Shares issued in private placements, net of offering costs	969,372	355	0	969,017	0
Shares issued in private placements, net of offering costs (in shares)	'	3,555,220	'	'	'
Stock-based compensation expense	97,400	0	0	97,400	0
Stock-based compensation expense (in shares)	'	0	'	'	'
Net loss	-562,084	0	0	0	-562,084
Balance at Dec. 31, 2006	552,564	2,658	0	1,128,114	-578,208
Balance (in shares) at Dec. 31, 2006	'	26,582,183	'	'	'
Shares issued in private placements, net of offering costs	531,320	100	0	531,220	0
Shares issued in private placements, net of offering costs (in shares)	'	999,995	'	'	'
Stock-based compensation expense	890,694	25	0	890,669	0
Stock-based compensation expense (in shares)	'	250,000	'	'	'
Stock-based research and development expense	50,836	0	0	50,836	0
Stock-based research and development expense (in shares)	'	0	'	'	'
Net loss	-1,648,488	0	0	0	-1,648,488
Balance at Dec. 31, 2007	376,926	2,783	0	2,600,839	-2,226,696
Balance (in shares) at Dec. 31, 2007	'	27,832,178	'	'	'
Stock-based compensation expense	357,987	0	0	357,987	0
Stock-based compensation expense (in shares)	'	0	'	'	'
Stock-based research and development expense	213,061	10	0	213,051	0
Stock-based research and development expense (in shares)	'	100,000	'	'	'
Net loss	-1,271,522	0	0	0	-1,271,522
Balance at Dec. 31, 2008	-323,548	2,793	0	3,171,877	-3,498,218
Balance (in shares) at Dec. 31, 2008	'	27,932,178	'	'	'
Shares issued in private placements, net of offering costs	1,097,050	242	0	1,096,808	0
Shares issued in private placements, net of offering costs (in shares)	'	2,420,000	'	'	'
Advances under equity financing	1,200,000	0	1,200,000	0	0
Stock-based compensation expense	745,980	15	0	745,965	0
Stock-based compensation expense (in shares)	'	150,000	'	'	'
Stock-based research and development expense	132,933	0	0	132,933	0
Stock-based research and development expense (in shares)	'	0	'	'	'
Net loss	-1,551,333	0	0	0	-1,551,333
Balance at Dec. 31, 2009	1,301,082	3,050	1,200,000	5,147,583	-5,049,551
Balance (in shares) at Dec. 31, 2009	'	30,502,178	'	'	'
Shares issued in private placements, net of offering costs	1,087,500	458	-1,200,000	2,287,042	0
Shares issued in private placements, net of offering costs (in shares)	'	4,575,000	'	'	'
Stock-based compensation expense	160,712	0	0	160,712	0
Stock-based compensation expense (in shares)	'	0	'	'	'
Stock-based research and development expense	67,222	0	0	67,222	0
Stock-based research and development expense (in shares)	'	0	'	'	'
Net loss	-880,250	0	0	0	-880,250
Balance at Dec. 31, 2010	1,736,266	3,508	0	7,662,559	-5,929,801
Balance (in shares) at Dec. 31, 2010	'	35,077,178	'	'	'
Exercise of stock options	5,000	18	0	4,982	0
Exercise of stock options (in shares)	'	181,964	'	'	'
Stock-based compensation expense	204,898	0	0	204,898	0
Stock-based compensation expense (in shares)	'	0	'	'	'
Stock-based research and development expense	982	0	0	982	0
Stock-based research and development expense (in shares)	'	0	'	'	'
Fair value of warrant extensions	199,839	0	0	199,839	0
Net loss	-2,067,964	0	0	0	-2,067,964
Balance at Dec. 31, 2011	79,021	3,526	0	8,073,260	-7,997,765
Balance (in shares) at Dec. 31, 2011	'	35,259,142	'	'	'
Exercise of stock options	33,333	24	0	33,309	0
Exercise of stock options (in shares)	'	241,955	'	'	'
Exercise of stock warrants	2,468,250	608	0	2,467,642	0
Exercise of stock warrants (in shares)	'	6,082,000	'	'	'
Stock-based compensation expense	723,554	0	0	723,554	0
Stock-based compensation expense (in shares)	'	0	'	'	'
Stock-based research and development expense	293,450	0	0	293,450	0
Stock-based research and development expense (in shares)	'	0	'	'	'
Fair value of warrant discount	334,024	0	'	334,024	0
Fair value of warrant extensions	1,139,592	0	0	1,139,592	0
Net loss	-3,579,366	0	0	0	-3,579,366
Balance at Dec. 31, 2012	1,491,858	4,158	0	13,064,831	-11,577,131
Balance (in shares) at Dec. 31, 2012	'	41,583,097	'	'	'
Stock-based compensation expense	119,250	0	0	119,250	0
Stock-based compensation expense (in shares)	'	0	'	'	'
Net loss	-1,374,842	0	0	0	-1,374,842
Balance at Dec. 31, 2013	$236,266	$4,158	$0	$13,184,081	($12,951,973)
Balance (in shares) at Dec. 31, 2013	'	41,583,097	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended		101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flows from operating activities:	'	'	'
Net loss	($1,374,842)	($3,579,366)	($12,951,973)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	0	0	1,909
Stock-based compensation expense included in general and administrative costs	119,125	723,554	3,300,100
Stock-based compensation expense included in research and development costs	125	293,450	758,609
Fair value of warrant extensions	0	1,139,592	1,339,431
Fair value of warrant discount	0	334,024	334,024
Changes in operating assets and liabilities:	'	'	'
Advances on research and development contract services	17,695	-22,592	-33,880
Prepaid expenses and other current assets	-2,827	-4,825	-43,006
Increase (decrease) in -	'	'	'
Accounts payable and accrued expenses	27,358	-28,925	107,774
Liquidated damages payable under registration rights agreement	0	0	74,000
Research and development contract liabilities	33,264	-60,669	47,283
Net cash used in operating activities	-1,180,102	-1,205,757	-7,065,729
Cash flows from investing activities:	'	'	'
(Increase) decrease in money market funds	-1	344,995	-6,135
Purchase of office equipment	0	0	-1,909
Net cash provided by (used in) investing activities	-1	344,995	-8,044
Cash flows from financing activities:	'	'	'
Proceeds from exercise of stock options	0	33,333	38,333
Proceeds from exercise of warrants	0	2,468,250	2,468,250
Proceeds from sale of common stock to consulting firm	0	0	250
Proceeds from sale of common stock to founder	0	0	1,500
Proceeds from issuance of notes payable to consultant	0	0	200,000
Repayment of notes payable to consultant	0	0	-200,000
Cash acquired in reverse merger transaction	0	0	62,500
Gross proceeds from sale of securities	0	0	5,331,389
Payment of private placement offering costs	0	0	-446,147
Advances received from stockholder	0	0	92,717
Net cash provided by financing activities	0	2,501,583	7,548,792
Cash:	'	'	'
Net increase (decrease)	-1,180,103	1,640,821	475,019
Balance at beginning of period	1,655,122	14,301	0
Balance at end of period	475,019	1,655,122	475,019
Supplemental disclosures of cash flow information:	'	'	'
Interest	0	0	2,469
Income taxes	0	0	0
Non-cash financing activities:	'	'	'
Decrease in advances under equity financing	0	0	1,200,000
Aggregate exercise price of warrants and options exercised on a cashless basis	$0	$109,391	$193,598

Organization_and_Business_Oper

Organization and Business Operations	12 Months Ended
	Dec. 31, 2013
Organization and Business Operations [Abstract]	'
Organization and Business Operations [Text Block]	'
	1. Organization and Business Operations
	Organization
	On June 30, 2006, Lixte Biotechnology, Inc., a privately-held Delaware corporation (“Lixte”) incorporated on August 9, 2005, completed a reverse merger transaction with SRKP 7, Inc. (“SRKP”), a non-trading public shell company, whereby Lixte became a wholly-owned subsidiary of SRKP. On December 7, 2006, SRKP amended its Certificate of Incorporation to change its name to Lixte Biotechnology Holdings, Inc.
	For financial reporting purposes, Lixte was considered the accounting acquirer in the merger and the merger was accounted for as a reverse merger. Accordingly, the historical financial statements presented herein are those of Lixte. The stockholders’ equity section of SRKP was retroactively restated for all periods presented to reflect the accounting effect of the reverse merger transaction. All costs associated with the reverse merger transaction were expensed as incurred.
	The Company is considered a “development stage company” under current accounting standards, as it has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and is dependent on debt and equity funding to finance its operations.
	The Company’s common stock is presently traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”.
	Operating Plans
	The Company’s primary focus is developing new treatments for human cancers for which better therapies are urgently needed. However, the scope of potential applications of the Company’s products has expanded to other common non-malignant diseases, including vascular diseases (heart attacks and stroke, diabetes, and genetic diseases, such as Gaucher’s disease) in which errors in normal cellular processing lead to loss of functions important to normal cell function. This has occurred because the targets selected by the Company have multiple functions in the cell, which when altered result in different disorders that may benefit by treatment from the Company’s products.
	The Company’s drug discovery process is based on discerning clues to potential new targets for disease treatments reported in the increasingly large body of literature identifying the molecular variants which characterize human cancers and other non-cancer disorders. The Company designs drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. The Company seeks to rapidly arrive at patentable structures through analysis of the literature rather than screening of thousands of structures for activity against a particular biochemical pathway. This approach has led to the development of two classes of drugs for the treatment of cancer, protein phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. Compounds of both types also have potential use in the prevention and treatment of neurodegenerative diseases.
	On August 16, 2011, the United States Patent and Trademark Office (the “PTO”) awarded a patent to the Company for its lead compound, LB-100, as well as for a number of structurally related compounds. On November 15, 2011, the PTO awarded a patent to the Company for a lead compound in the LB-200 series and a compound in the LB-100 series as neuroprotective agents for the prevention and treatment of neurodegenerative diseases. On March 27, 2012, the PTO awarded a patent to the Company for its lead compound LB-201, as well as for a number of structurally related compounds. Patent applications on these compounds and their use are pending world-wide.
	The Company’s primary objective has been to bring one lead compound of the LB-100 series to clinical trial. In 2012, the Company completed the pre-clinical studies needed to prepare an Investigation New Drug (“IND”) application to the FDA to conduct a Phase 1 clinical trial of LB-100, and engaged  Theradex Systems, Inc. (“Theradex”), the contract research organization (“CRO”) responsible for the clinical development of the Company’s lead compound, LB-100, to prepare an IND application for filing with the FDA.
	The Company filed an IND application with the FDA on April 30, 2012, and on July 24, 2012, the FDA notified the Company that it would allow initiation of a Phase 1 clinical trial of LB-100. The purpose of the clinical trial is to demonstrate that LB-100 can be administered safely to human beings at a dose and at a frequency that achieves the desired pharmacologic effect; in this case, inhibition of a specific enzyme, without being associated with toxicities considered unacceptable.
	The Phase 1 clinical trial of LB-100 began in April 2013 with the entry of patients into the clinical trial (see NCTO 1837667 at www.clinicaltrials.gov) and was initiated at the City of Hope National Medical Center in Duarte, California, and was extended in December 2013 to include the Mayo Clinic in Rochester, Minnesota, both of which are Comprehensive Cancer Centers designated by the National Cancer Institute. The Company estimates that the Phase 1 clinical trial will be completed within the next 12 to 21 months (sometime between March and December 2015) and will cost a total of approximately $2,000,000, which will be paid to or through Theradex, the CRO responsible for the clinical development of LB-100.  As of December 31, 2013, the Company has incurred $278,721 of these clinical trial costs, which have been included in research and development expenses in the statement of operations for the year ended December 31, 2013.. The final cost of the clinical trial is variable, depending upon the number of patients needed to be medically screened to determine if they meet the criteria for entry into the study and ultimately upon the total number of patients entered into the study to establish the proper doses of the drug for Phase 2 clinical trials.
	The Company’s approach has been to operate with a minimum of overhead, moving compounds forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain milestones are reached. The commencement of a Phase 1 clinical trial is a milestone in the Company’s goal of developing a successful product platform.
	Going Concern
	The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is in the development stage and has not generated any revenues from operations to date, and does not expect to do so in the foreseeable future. The Company has experienced recurring operating losses and negative operating cash flows since inception, and has financed its working capital requirements during this period primarily through the recurring sale of its equity securities and the exercise of outstanding warrants. As a result, the Company’s independent registered public accounting firm, in its report on the Company’s 2013 consolidated financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern.
	The Company’s ability to continue as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
	At December 31, 2013, the Company had not yet commenced any revenue-generating operations. All activity through December 31, 2013 has been related to the Company’s formation, capital raising efforts, and research and development activities. As such, the Company has yet to generate any cash flows from operations, and is dependent on debt and equity funding from both related and unrelated parties to finance its operations. Prior to June 30, 2006, the Company’s cash requirements were funded by advances from the Company’s founder aggregating $92,717.
	Because the Company is currently engaged in research at an early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating revenues. As such, the Company’s business is unlikely to generate any sustainable revenues in the next several years, and may never do so. Even if the Company is able to generate revenues in the future through licensing its technologies or through product sales, there can be no assurance that the Company will be able to achieve positive earnings and cash flows from operations.
	The Company’s major focus in 2014 is to continue a Phase 1 clinical trial of its lead phosphatase inhibitor, LB-100. The Phase 1 clinical trial of LB-100 began in April 2013 with the entry of patients into the clinical trial, and is being carried out by nationally recognized comprehensive cancer centers. The cost of a clinical trial depends to a considerable extent upon the rate of patient accrual, as well as the number of patients entered into the clinical trial.  If screening tests render a patient ineligible for the clinical trial, the screening costs are realized, but patient accrual is not advanced.  Accordingly, the costs needed to complete a clinical trial with the planned number of participants may increase under such circumstances.
	The Company estimates that the Phase 1 clinical trial will conclude within the next 12 to 21 months (sometime between March and December 2015) and will cost a total of approximately $2,000,000, which will be paid to or through Theradex, the CRO responsible for the clinical development of LB-100.  As of December 31, 2013, the Company has incurred $278,721 of these clinical trial costs, which have been included in research and development expenses in the statement of operations for the year ended December 31, 2013.
	At December 31, 2013, the Company had cash and money market funds aggregating $481,154. The Company believes that it has sufficient funds to continue with the Phase 1 clinical trial of LB-100 and to fund its operating plans through April 30, 2014. Accordingly, in order to continue to fund the Company’s operations in 2014 and thereafter,  the Company will need to raise additional capital, likely in the form of equity, aggregating at least $2,000,000 to fund operations for the next twelve months.  Market conditions present uncertainty as to the Company’s ability to secure additional funds. There can be no assurances that the Company will be able to secure additional financing on acceptable terms or at all. If cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to certain of its products, or to discontinue its operations entirely.
	The amount and timing of future cash requirements will depend on the pace of the Company’s programs, particularly the completion of the Phase 1 clinical trial of LB-100. After completion of the Phase 1 clinical trial, the next step will be to determine the anti-cancer activity of LB-100, in combination with a widely used anti-cancer drug, against a specific type of human cancer in Phase 2 clinical trials. Subject to the availability of funds, the Company intends to continue with its Phase 1 clinical trial of LB-100, continue the two drug development programs currently in process, and expand its patent portfolio, including the maintenance of its applications for international protection of lead compounds of both the LB-100 and LB-200 series.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2. Summary of Significant Accounting Policies
	Principles of Consolidation
	The accompanying consolidated financial statements include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. All intercompany balances and transactions have been eliminated in consolidation.
	Cash Concentrations
	The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.
	Research and Development
	Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates.
	Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s balance sheet and then charged to research and development costs in the Company’s statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s balance sheet, with a corresponding charge to research and development costs in the Company’s statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.
	Patent Costs
	Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company's research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $405,285 and $236,784 for the years ended December 31, 2013 and 2012, respectively, and $1,814,682 for the period from August 9, 2005 (inception) to December 31, 2013 (cumulative). Patent costs are included in research and development costs in the Company's consolidated statements of operations.
	Royalties
	Pursuant to a Patent License Agreement with the NIH that provides the Company with an exclusive license for all patents submitted jointly with the NIH under the CRADA, various categories of royalties at various rates and amounts are payable, including minimum annual royalties (subject to an offset for royalties from net sales), royalties on net sales, royalties based on the achievement of certain benchmarks, and royalties based on granting sublicense agreements, with respect to joint patents. Such royalties are accrued and paid when they become legal obligations, and are charged to general and administrative costs.
	Concentration of Risk
	The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task, and can include both cash and non-cash compensation.  The only such contract that represents 10% or more of general and administrative or research and development costs is described below.
	On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. Theradex is an international CRO that provides professional services for the clinical research and development of pharmaceutical compounds. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed within the next 12 to 21 months (sometime between March and December 2015). The Phase 1 clinical trial is expected to cost a total of approximately $2,000,000, with such payments expected to be divided approximately evenly between payments to Theradex for services rendered and payments for pass-through costs for the clinical center’s laboratory costs and investigator costs. Total costs charged to operations for services paid to Theradex pursuant to this arrangement, which were first incurred in 2013, were $278,721 for the year ended December 31, 2013, or approximately 32% of research and development costs for the year ended December 31, 2013. The costs charged to operations for amounts paid to Theradex for services relating to the Phase 1 clinical trial of LB-100 are expected to represent a larger percentage of total research and development costs during the fiscal years ending December 31, 2014 and 2015. Costs pursuant to this agreement are included in research and development costs in the Company's consolidated statements of operations. On May 2, 2011, Dr. Robert B. Royds, the founder, Chairman of the Board and Medical Director of Theradex, was appointed to the Company’s Board of Directors. Dr. Royds died on March 23, 2013. The death of Dr. Royds is not expected to have any impact on the management and administration of the Phase 1 clinical trial.
	In addition to the above described agreement with Theradex, the Company has also from time to time engaged Theradex to assist the Company in bringing LB-100 through the FDA approval process and to provide other services. Total fees charged to operations for services paid to Theradex pursuant to such engagements were $14,964 and $163,661 for the years ended December 31, 2013 and 2012, respectively, or approximately 2% and 16% of research and development costs for the years ended December 31, 2013 and 2012, respectively, and are included in research and development costs in the Company's consolidated statements of operations.
	Income Taxes
	The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.
	The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period.
	The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.
	For federal income tax purposes, net operating losses can be carried forward for a period of 20 years until they are either utilized or until they expire.
	On January 1, 2007, the Company adopted accounting rules which address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under these rules, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. These accounting rules also provide guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of December 31, 2013, no liability for unrecognized tax benefits was required to be recorded.
	The Company files income tax returns in the U.S. federal jurisdiction and is subject to income tax examinations by federal tax authorities for the year 2009 and thereafter. The Company’s policy is to record interest and penalties on uncertain tax provisions as income tax expense. As of December 31, 2013, the Company has no accrued interest or penalties related to uncertain tax positions.
	Stock-Based Compensation
	The Company periodically issues stock options and warrants to officers, directors and consultants for services rendered. Options vest and expire according to terms established at the grant date.
	The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in the Company’s financial statements on a straight-line basis over the vesting period of the awards.
	The Company accounts for stock-based payments to consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.
	Options granted to members of the Company’s Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.
	Earnings Per Share
	The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.
	Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive.
	At December 31, 2013 and 2012, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.
		2013		2012
	Warrants		6,828,800		6,828,800
	Stock options		3,150,000		3,750,000
	Total		9,978,800		10,578,800
	Fair Value of Financial Instruments
	The carrying amounts of cash, money market funds, advances on research and development contract services, prepaid expenses and other current assets, accounts payable and accrued expenses, research and development contract liabilities, liquidated damages payable under registration rights agreement and due to stockholder approximate their respective fair values due to the short-term nature of these items.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2013-04, Liabilities (Topic 405): Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date.  This guidance provides direction for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this guidance is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. This guidance will become effective for the Company for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s consolidated financial statements.
	In March 2013, the FASB issued ASU No. 2013-05, Foreign Currency Matters (Topic 830). This guidance resolves the diversity in practice relating to financial reporting involving a parent entity’s accounting for the cumulative translation adjustment of foreign currency into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, this guidance resolves the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. This guidance will become effective for the Company for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s consolidated financial statements.
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Loss, or a Tax Credit Carryforward Exists (a consensus the FASB Emerging Issues Task Force). This guidance provides direction on financial statement presentation of unrecognized tax benefit when a net operating loss carrforward, a similar tax loss, or a tax credit carryforward exists. The FASB’s objective in issuing this guidance was to eliminate diversity in practice resulting from a lack of guidance on this topic in current U.S. GAAP. This guidance applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date. This guidance will become effective for the Company for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s consolidated financial statements.
	Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Share_Exchange_Agreement_Priva

Share Exchange Agreement, Private Placements and Common Stock Warrants	12 Months Ended
	Dec. 31, 2013
Share Exchange Agreement Private Placements and Common Stock Warrants [Abstract]	'
Share Exchange Agreement Private Placements and Common Stock Warrants [Text Block]	'
	3. Share Exchange Agreement, Private Placements and Common Stock Warrants
	Share Exchange Agreement
	On June 30, 2006, pursuant to a Share Exchange Agreement dated as of June 8, 2006 (the “Share Exchange Agreement”) by and among the Company, Dr. John S. Kovach (“Seller”) and Lixte, the Company issued 19,021,786 shares of its common stock in exchange for all of the issued and outstanding shares of Lixte (the “Exchange”). Previously, on October 3, 2005, Lixte had issued 1,500 shares of its no par value common stock to its founder for $1,500, which constituted all of the issued and outstanding shares of Lixte prior to the Exchange. As a result of the Exchange, Lixte became a wholly-owned subsidiary of the Company.
	Pursuant to the Exchange, the Company issued to the Seller 19,021,786 shares of its common stock. The Company had a total of 25,000,832 shares of common stock issued and outstanding after giving effect to the Exchange and the 1,973,869 shares of common stock issued in the initial closing of the private placement.
	As a result of the Exchange and the shares of common stock issued in the initial closing of the private placement, on June 30, 2006, the stockholders of the Company immediately prior to the Exchange owned 4,005,177 shares of common stock, equivalent to approximately 16% of the issued and outstanding shares of the Company’s common stock, and the former stockholder of Lixte acquired control of the Company.
	In connection with the Exchange, the Company paid WestPark Capital, Inc. a cash fee of $50,000.
	Private Placements
	On June 30, 2006, concurrently with the closing of the Exchange, the Company sold an aggregate of 1,973,869 shares of its common stock to accredited investors in an initial closing of a private placement at a per share price of $0.333, resulting in aggregate gross proceeds to the Company of $657,299. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.333 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.333 per share. A total of 236,864 warrants were issued. Net cash proceeds to the Company, after the deduction of all private placement offering costs and expenses, were $522,939.
	On July 27, 2006, the Company sold an aggregate of 1,581,351 shares of its common stock to accredited investors in a second closing of the private placement at a per share price of $0.333 resulting in aggregate gross proceeds to the Company of $526,590. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.333 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.333 per share. A total of 189,762 warrants were issued. Net cash proceeds to the Company were $446,433.
	In conjunction with the private placement of common stock, the Company issued a total of 426,626 five-year warrants to WestPark Capital, Inc. exercisable at the per share price of the common stock sold in the private placement ($0.333 per share). The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contained cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company’s consolidated financial statements.
	As part of the Company’s private placement of its securities completed on July 27, 2006, the Company entered into a registration rights agreement with the purchasers, whereby the Company agreed to register the shares of common stock sold in the private placement, and to maintain the effectiveness of such registration statement, subject to certain conditions. The agreement required the Company to file a registration statement within 45 days of the closing of the private placement and to have the registration statement declared effective within 120 days of the closing of the private placement. On September 8, 2006, the Company filed a registration statement on Form SB-2 to register 3,555,220 shares of the common stock sold in the private placement. Since the registration statement was not declared effective by the Securities and Exchange Commission within 120 days of the closing of the private placement, the Company was required to pay each investor prorated liquidated damages equal to 1.0% of the amount raised per month, payable monthly in cash.
	On the date of the closing of the private placement, the Company believed it would meet the deadlines under the registration rights agreement with respect to filing a registration statement and having it declared effective by the Securities and Exchange Commission. As a result, the Company did not record any liabilities associated with the registration rights agreement at June 30, 2006. At December 31, 2006, the Company determined that the registration statement covering the shares sold in the private placement would not be declared effective within the requisite time frame and therefore recorded a current liability representing six months liquidated damages under the registration rights agreement aggregating approximately $74,000. The Company’s registration statement on Form SB-2 was declared effective by the Securities and Exchange Commission on May 14, 2007. At December 31, 2013, the registration penalty payable to the investors had not been paid, and has been included in the Company’s balance sheet as a current liability for all periods presented.
	On December 12, 2007, the Company sold an aggregate of 999,995 shares of its common stock to accredited investors in a second private placement at a per share price of $0.65, resulting in aggregate gross proceeds to the Company of $650,000. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the private placement exercisable at $0.65 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.65 per share. Net cash proceeds to the Company were $531,320.
	In conjunction with the second private placement of common stock, the Company issued a total of 120,000 five-year warrants to WestPark Capital, Inc. exercisable at the per share price of the common stock sold in the private placement ($0.65 per share). The warrants issued to WestPark Capital, Inc. did not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company’s consolidated financial statements. On December 12, 2012, the above described warrants expired unexercised.
	As part of the Company’s second private placement of its securities completed on December 12, 2007, the Company entered into a registration rights agreement with the purchasers, whereby the Company agreed to register the shares of common stock sold in the second private placement at its sole cost and expense. The registration rights agreement terminates at such time as the common shares may be sold in market transactions without regard to any volume limitations. The registration rights agreement requires the Company to file a registration statement within 75 days of receipt of written demand from holders who represent at least 50% of the common shares issued pursuant to the second private placement, provided that no demand shall be made for less than 500,000 shares, and to use its best efforts to cause such registration statement to become and remain effective for the requisite period. The registration rights agreement also provides for unlimited piggyback registration rights. The registration rights agreement does not provide for any penalties in the event that the Company is unable to comply with its terms.
	During the year ended December 31, 2009, the Company completed three closings of the third private placement of common stock units, consisting of a total of 1,420,000 shares of common stock and 1,420,000 warrants to acquire common stock, as follows:
	On February 10, 2009, the Company sold an aggregate of 658,000 common stock units to accredited investors in a first closing of a third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $329,000. Net cash proceeds to the Company were $269,790.
	On March 2, 2009, the Company sold an aggregate of 262,000 common stock units to accredited investors in a second closing of the third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $131,000. Net cash proceeds to the Company were $112,460.
	On April 6, 2009, the Company sold an aggregate of 500,000 common stock units to accredited investors in a third closing of the third private placement at a per unit price of $0.50, resulting in aggregate gross proceeds to the Company of $250,000. Net cash proceeds to the Company were $214,800.
	Each unit sold in the third private placement consisted of one share of the Company’s common stock and a five-year warrant to purchase an additional share of the Company’s common stock on a cashless exercise basis at an exercise price of $0.50 per common share. The Company paid to WestPark Capital, Inc., as placement agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds of the third private placement and issued five-year warrants to purchase common stock equal to (a) 10% of the number of shares sold in the third private placement exercisable at $0.50 per share and 10% of the number of shares issuable upon exercise of warrants issued in the third private placement exercisable at $0.50 per share; and (b) an additional 2% of the number of shares sold in the third private placement also exercisable at $0.50 per share and 2% of the number of shares issuable upon exercise of the warrants issued in the third private placement exercisable at $0.50 per share.
	In conjunction with the closings of the third private placement of common stock units during the year ended December 31, 2009, the Company issued a total of 340,800 five-year warrants to WestPark Capital, Inc., which are exercisable at the per unit price of the common stock units sold in the third private placement ($0.50 per unit). Included in the 340,800 warrants issued to WestPark Capital, Inc. are 170,400 warrants which are only exercisable with respect to common shares that are acquired by investors upon their exercise of the warrants acquired as part of the units sold in the third private placement. The warrants issued to WestPark Capital, Inc. do not contain any price anti-dilution provisions. However, such warrants contain cashless exercise provisions and demand registration rights, but the warrant holder has agreed to waive any claims to monetary damages or financial penalties for any failure by the Company to comply with such registration requirements. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company’s consolidated financial statements. On May 10, 2012, warrants to purchase 1,440 shares of common stock were exercised.
	At the request of the holders, the Company has agreed to include any shares sold in the third private placement and any shares issuable upon exercise of the related warrants to be included in any registration statement filed with the Securities and Exchange Commission permitting the resale of such shares, subject to customary cutbacks, at the Company’s sole cost and expense.
	Effective November 6, 2009, the Company sold 1,000,000 common stock units to an accredited investor in a fourth private placement at a per unit price of $0.50, resulting in proceeds to the Company of $500,000. There were no commissions paid with respect to the fourth private placement. The closing price of the Company’s common stock on November 6, 2009 was $0.50 per share.
	Each unit sold in the fourth private placement consisted of one share of the Company’s common stock, one three-year warrant to purchase an additional share of the Company’s common stock at an exercise price of $0.50 per share, and one three-year warrant to purchase an additional share of the Company’s common stock at an exercise price of $0.75 per share. The warrants do not have any reset provisions.
	At the request of the holder, the Company has agreed to include the shares sold in the fourth private placement and any shares issuable upon exercise of the related warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Securities Act of 1933, as amended (the “Act”), in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. Based on the foregoing, the warrants were accounted for as equity and were not accounted for separately from the common stock and additional paid-in capital accounts. The warrants had no accounting impact on the Company’s consolidated financial statements.
	Effective January 20, 2010, the Company raised $1,787,500 in a fifth private placement of units sold to certain of its existing stockholders or their designees, all of whom were accredited investors, consisting of an aggregate of 3,575,000 units at a purchase price of $0.50 per unit. Each unit consisted of one share of common stock, one three-year warrant to purchase a share of common stock at an exercise price of $0.50 per share, and one three-year warrant to purchase a share of common stock at an exercise price of $0.75 per share. The warrants do not have any reset provisions. The closing price of the Company’s common stock on January 20, 2010 was $0.49 per share. There were no commissions paid with respect to the private placement. Upon request by the holder, the Company has agreed to include the shares issued and those shares issuable upon exercise of the warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Act, in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. The Company accounted for the issuance of the units as a capital transaction. As of December 31, 2009, $1,200,000 had been advanced to the Company under this private placement, with the balance of $587,500 being received by the Company in January 2010.
	Effective February 22, 2010, the Company raised $500,000 through the sale to an accredited investor of 1,000,000 units at a purchase price of $0.50 per unit. Each unit consisted of one share of common stock, one three-year warrant to purchase a share of common stock at an exercise price of $0.50 per share, and one three year-year warrant to purchase a share of common stock at an exercise price of $0.75 per share. The warrants do not have any reset provisions. The closing price of the Company’s common stock on February 22, 2010 was $0.50 per share. There were no commissions paid with respect to the private placement. Upon request by the holder, the Company has agreed to include the shares issued and those shares issuable upon exercise of the warrants in any registration statement filed by the Company with the Securities and Exchange Commission permitting the resale of such securities, subject to customary cutbacks. The units sold were not registered under the Act, in reliance upon the exemption from registration contained in Section 4(2) of the Act and Regulation D promulgated thereunder. The Company accounted for the issuance of the units as a capital transaction.
	If and when the aforementioned stock warrants are exercised, the Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.
	Common Stock Warrants
	On July 27, 2009, the Company entered into an agreement with Pro-Active Capital Group, LLC (“Pro-Active”) to retain Pro-Active on a non-exclusive basis for a period of twelve months to provide consulting advice to assist the Company in obtaining research coverage, gaining web-site exposure and coverage on financial blogs and web-sites, enhancing the Company’s visibility to the institutional, retail brokerage and on-line trading communities, and organizing, or assisting in organizing, investor road-shows and presentations. In exchange for such consulting advice, at the initiation of the agreement, the Company agreed to issue to Pro-Active 150,000 shares of restricted common stock and three-year warrants to purchase an aggregate of 150,000 shares of common stock, exercisable 50,000 at $0.75 per share, 50,000 at $1.00 per share, and 50,000 at $1.25 per share. The fair value of the 150,000 shares issued was determined to be $100,500 ($0.67 per share), reflecting the price per share of the Company’s common stock, as quoted on the OTC Bulletin Board, on the transaction date. The fair value of the three-year warrants, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $97,500 ($0.65 per share). The $198,000 aggregate fair value of the shares and warrants issued was charged to operations as stock-based compensation on July 27, 2009, since the shares and warrants were fully vested and non-forfeitable on the date of issuance. On July 27, 2012, the above described warrants expired unexercised.
	On June 30, 2011, WestPark Capital, Inc. exercised warrants to acquire 152,874 shares of common stock, obtained in connection with its role as placement agent for the June 30, 2006 private placement, on a cashless basis. Such cashless exercise resulted in WestPark Capital, Inc. receiving a net of 100,929 shares of common stock.
	On July 27, 2011, the Company agreed to extend the remaining portion of the warrants obtained by WestPark Capital, Inc. in connection with its role as placement agent for the June 30, 2006 private placement, consisting of warrants to acquire 273,752 shares of common stock, from July 27, 2011 to July 27, 2012. In conjunction with the extension of these warrants, the cashless exercise feature was deleted. The fair value of the warrant extension, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $199,839 ($0.73 per share), and was charged to operations on July 27, 2011. The fair value of the warrant extension was calculated using the following input variables: stock price - $0.79 per share; exercise price - $0.333 per share; expected life - 1 year; expected volatility – 308.8%; expected dividend yield - 0%; risk-free interest rate – 0.14%.
	On July 16, 2012, the Company’s Board of Directors agreed to permit the exercise of the above described warrants to acquire 273,752 shares of common stock of the Company on a cashless basis, provided that the cashless exercise price was increased by 20%, from $0.333 to $0.3996 per share. Accordingly, on July 16, 2012, warrants to acquire 273,752 shares of common stock, issued in connection with WestPark Capital, Inc.’s role as placement agent for the June 30, 2006 private placement, were exercised on a cashless basis. Such cashless exercise resulted in the net issuance of 141,955 shares of common stock. The Company’s closing stock price on July 16, 2012 was $0.83 per share. As the fair value of the warrants immediately after the modification was less than the fair value of the warrants immediately prior to the modification (both amounts being calculated pursuant to the Black-Scholes option-pricing model), the Company did not record any accounting adjustment with respect to the warrant modification.
	On May 3, 2012, the Company offered to all of its warrant holders an inducement to exercise early, by reducing the exercise price of currently outstanding warrants by 25%, if exercised on a cash basis by June 15, 2012. The exercise prices of the warrants before reduction ranged from $0.333 to $1.25 per share, and the offer was open until the sooner of receiving $3,000,000 in net proceeds, or June 15, 2012, subject to the Company’s right to extend the offer to June 30, 2012. The offer was subject to certain conditions. As a result of the discount warrant offer, warrants to acquire 6,082,000 shares of the Company’s common stock were exercised at discounts ranging from $0.125 to $0.188 per share. The exercise of the warrants generated aggregate net proceeds to the Company of $2,468,250. The aggregate fair value of the warrant discounts, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $334,024 (an average of $0.05 per share issued), and such amount was charged to operations during the months of May and June of 2012. The fair value of the warrant discounts attributed to the exercise of 5,082,000 warrants was calculated using the following input variables: stock price on date of exercise - $0.69 to $0.84 per share; stated exercise price – $0.50; discounted exercise price – $0.375 per share; expected life – 157 days to 661 days; expected volatility – 150.1%; expected dividend yield - 0%; risk-free interest rate – 0.24%. The fair value of the warrant discounts attributed to the exercise of 1,000,000 warrants was calculated using the following input variables: stock price on date of exercise - $0.69 per share; stated exercise price – $0.75; discounted exercise price – $0.563 per share; expected life – 157 days; expected volatility – 150.1%; expected dividend yield - 0%; risk-free interest rate – 0.24%.
	On September 11, 2012, the Company’s Board of Directors extended outstanding warrants to acquire 5,080,000 shares of the Company’s common stock that were purchased by investors as part of the offerings that closed on January 20, 2010 and February 22, 2010, to June 30, 2014. Included in such extension were warrants to acquire 505,000 shares of common stock at $0.50 per share scheduled to expire on January 20, 2013, warrants to acquire 3,575,000 shares of common stock at $0.75 per share scheduled to expire on January 20, 2013, and warrants to acquire 1,000,000 shares at $0.75 per share scheduled to expire on February 22, 2013. The fair value of the warrant extensions, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $1,139,592 (average of $0.22 per share), and such amount was charged to operations on September 11, 2012. The fair value of the warrant extensions were calculated using the following input variables: stock price - $0.65 per share; exercise price - $0.50 and $0.75 per share; expected life – 526 days and 493 days; expected volatility – 148.4%; expected dividend yield - 0%; risk-free interest rate – 0.29%.
	A summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s private placements, is presented in the tables below. For presentation purposes, warrants that were extended are considered as outstanding for the entire period in which such extension occurs.
							Weighted
							Average
					Weighted		Remaining
			Number		Average		Contractual
			of		Exercise		Life
			Shares		Price		(in Years)
	Warrants outstanding at December 31, 2011			13,454,552	$	0.607
	Issued			—		—
	Exercised			-6,355,752		0.535
	Expired			-270,000		0.844
	Warrants outstanding at December 31, 2012			6,828,800		0.667
	Issued			—		—
	Exercised			—		—
	Expired			—		—
	Warrants outstanding at December 31, 2013			6,828,800	$	0.667		0.67
	Warrants exercisable at December 31, 2012			6,659,840	$	0.672
	Warrants exercisable at December 31, 2013			6,659,840	$	0.672		0.42
	The exercise prices of common stock warrants outstanding and exercisable are as follows at December 31, 2013:
				Warrants	Warrants
	Exercise			Outstanding	Exercisable
	Prices			(Shares)	(Shares)
	$	0.5		2,253,800	2,084,840
	$	0.75		4,575,000	4,575,000
				6,828,800	6,659,840
	Based on a fair market value of $0.13 per share on December 31, 2013, there were no exercisable but unexercised in-the-money common stock warrants on that date. Accordingly, there was no intrinsic value attributed to exercisable but unexercised common stock warrants at December 31, 2013.
	Based on a fair market value of $0.25 per share on December 31, 2012, there were no exercisable but unexercised in-the-money common stock warrants on that date. Accordingly, there was no intrinsic value attributed to exercisable but unexercised common stock warrants at December 31, 2012
	At December 31, 2013, warrants exercisable do not include warrants to acquire 168,960 shares of common stock that are contingent upon the exercise of warrants contained in units sold as part of the third private placement, as described above.
Effective January 28, 2014, the Company entered into various transactions involving its outstanding warrants, as described at Note 9.

Money_Market_Funds_Fair_Value

Money Market Funds - Fair Value	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
Money Market Funds Fair Value [Text Block]	'
	4. Money Market Funds — Fair Value
	Money market funds at December 31, 2013 and 2012 consisted of investments in shares of Morgan Stanley New York Municipal Money Market Trust with market values of $6,135 and $6,134, respectively. The Morgan Stanley New York Municipal Money Market Trust is an open-end fund incorporated in the USA. The Fund's objective is as high level of daily income exempt from federal and New York income tax as is consistent with stability of principal and liquidity. The Fund invests in high quality, short- term municipal obligations that pay interest exempt from federal and NY taxes.
	The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.
	Level 1: quoted prices (unadjusted) in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.
	Level 2: inputs other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.
	Level 3: unobservable inputs for the asset or liability are only used when there is little, if any, market activity for the asset or liability at the measurement date. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.
	The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.
	Money market funds are the only financial instrument that is measured and recorded at fair value on the Company’s balance sheet on a recurring basis.
	The following table presents money market funds at their level within the fair value hierarchy at December 31, 2013 and 2012.
		Total		Level 1		Level 2		Level 3
	December 31, 2013:
	Money market funds	$	6,135	$	6,135	$	—	$	—
	December 31, 2012:
	Money market funds	$	6,134	$	6,134	$	—	$	—

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	5. Related Party Transactions
	Prior to June 30, 2006, the Company’s founding stockholder and Chief Executive Officer, Dr. John Kovach, had periodically made advances to the Company to meet operating expenses. Such advances are non-interest-bearing and are due on demand. At December 31, 2013 and 2012, stockholder advances outstanding and due to Dr. Kovach totaled $92,717.
	The Company’s office facilities have been provided without charge by Dr. Kovach. Such costs were not material to the financial statements and, accordingly, have not been reflected therein.
	In view of the Company’s development stage status and limited resources, Dr. Kovach did not receive any compensation from the Company prior to 2011. However, on February 18, 2011, the Company’s Board of Directors approved a salary for Dr. Kovach of $5,000 per month beginning March 15, 2011.  Dr. Kovach was paid a salary of $60,000 for the years ended December 31, 2013 and 2012, and $167,500 for the period from August 9, 2005 (inception) to December 31, 2013 (cumulative), which amounts are included in general and administrative costs in the Company's consolidated statements of operations.
	Dr. Kovach is not involved in other business activities but could, in the future, become involved in other business opportunities that become available. Accordingly, he may face a conflict in selecting between the Company and his other business interests. The Company has not yet formulated a policy for the resolution of such potential conflicts.
	On April 7, 2010, the Company entered into an agreement with Dr. Mel Sorensen, a member of the Company’s Board of Directors, for consultation and advice regarding the preparation and strategy for obtaining FDA allowance of a clinical trial of the lead compound of the LB-100 series. The initial term of the agreement was for one year and provided for an annual fee of $25,000, payable in two installments of $12,500 on April 15, 2010 and October 15, 2010. On February 18, 2011, the Company’s Board of Directors approved a one-year extension of the agreement for an additional annual fee of $25,000, payable in two installments of $12,500 on April 15, 2011 and October 15, 2011. On May 21, 2012, the Company entered into a new agreement with Dr. Mel Sorensen for continuing consultation and advice. The term of the new agreement was for the period from May 21, 2012 to May 31, 2013 and provided for a fee of $25,000, payable in two installments of $12,500 on May 21, 2012 and December 1, 2012. All installments have been paid as due. Consulting and advisory fees charged to operations pursuant to these agreements were $10,417 and $21,875 for the years ended December 31, 2013 and 2012, respectively, and $75,000 for the period from August 9, 2005 (inception) to December 31, 2013 (cumulative), and are included in research and development costs in the Company's consolidated statements of operations.
	On September 21, 2012, the Company entered into a work order agreement with Theradex   to manage and administer the Phase 1 clinical trial of LB-100. Theradex is an international CRO that provides professional services for the clinical research and development of pharmaceutical compounds. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed within the next 12 to 21 months (sometime between March and December 2015).  The Phase 1 clinical trial is estimated to cost a total of approximately   $2,000,000, with such payments expected to be divided approximately evenly between payments to Theradex for services rendered and payments for pass-through costs for the clinical center’s laboratory costs and investigator costs. Total costs charged to operations for services paid to Theradex pursuant to this arrangement, which were first incurred in 2013, were $278,721 for the year ended December 31, 2013. Costs pursuant to this agreement are included in research and development costs in the Company's consolidated statements of operations. On May 2, 2011, Dr. Robert B. Royds, the founder, Chairman of the Board and Medical Director of Theradex, was appointed to the Company’s Board of Directors. Dr. Royds died on March 23, 2013. The death of Dr. Royds is not expected to have any impact on the management and administration of the Phase 1 clinical trial.
	In addition to the above described agreement with Theradex, the Company has also from time to time engaged Theradex to assist the Company in bringing LB-100 through the FDA approval process and to provide other services. Total fees charged to operations for services paid to Theradex pursuant to such engagements were $14,964 and $163,661 for the years ended December 31, 2013 and 2012, respectively, and $194,551 for the period from August 9, 2005 (inception) to December 31, 2013 (cumulative), and are included in research and development costs in the Company's consolidated statements of operations.
	On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. ("NDA") for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company's Scientific Advisory Committee. The term of the agreement was for one year and provides for a quarterly cash fee of $4,000. The first such quarterly cash payment was made on January 12, 2014. There were no consulting or advisory fees charged to operations pursuant to this quarterly cash fee prior to January 1, 2014. In connection with this agreement, NDA was granted stock options to purchase 100,000 shares of the Company’s common stock, vesting 25,000 shares on June 24, 2014, and 25,000 shares annually on June 24 thereafter 25,000 shares annually on June 24, 2015, 2016 and 2017, exercisable for a period of five years from the date of grant at $0.13 per share, which was the fair market value of the common stock on the grant date.
	Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Company’s Board of Directors, as described at Note 9.
	Stock-based compensation arrangements involving members of the Company’s Board of Directors are described at Note 6. Total stock-based compensation expense relating to directors, officers and other related parties was $119,250 and $1,017,004 for the years ended December 31, 2013 and 2012, respectively, and $3,598,461 for the period from August 9, 2005 (inception) to December 31, 2013 (cumulative).

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Share-Based Compensation [Abstract]	'
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Text Block]	'
	6. Stock-Based Compensation
	The Company grants stock options as incentive compensation to directors and as compensation for the services of independent contractors and consultants of the Company.
	The fair value of each option awarded is estimated on the date of grant and subsequent measurement dates using the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company’s stock options have characteristics significantly different from those of traded options, and because changes in the subjective assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its stock options. The expected dividend yield assumption is based on the Company’s expectation of dividend payouts. Expected volatilities are based on historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. treasury yield curve in effect as of the grant date. Expected life of the options is the average of the vesting term and the full contractual term of the options.
	New transactions during the year ended December 31, 2013 that required an assessment of value pursuant to the Black-Scholes option-pricing model utilized the following inputs: exercise price per share - $0.13; stock price per share – $0.13; expected dividend yield – 0.00%; expected volatility – 262.0%; average risk-free interest rate – 1.51%; expected life – 5 years. There were no transactions entered into in prior periods that required re-evaluation of assessed value at December 31, 2013.
	New transactions during the year ended December 31, 2012 that required an assessment of value pursuant to the Black-Scholes option-pricing model utilized the following inputs: exercise price per share - $0.65 to $1.00; stock price per share – $0.65; expected dividend yield – 0.00%; expected volatility – 148.4%; average risk-free interest rate – 0.78%; expected life – 5 years. For the purpose of assessing value for transactions requiring re-evaluation at December 31, 2012 that were entered into in prior periods, the Black-Scholes option-pricing model utilized the following inputs for the year ended December 31, 2012: exercise price per share - $0.98 to $1.00; stock price per share – $0.25; expected dividend yield – 0.00%; expected volatility – 128.4%; average risk-free interest rate – 0.24%; expected life – 3.50 to 4.00 years.
	As the Company’s common stock commenced trading on September 24, 2007, the Company was able to utilize such trading data to generate revised volatility factors as of the various measurement dates.
	On June 30, 2006, effective with the closing of the Exchange, the Company granted to Dr. Philip Palmedo, an outside director of the Company, stock options to purchase an aggregate of 200,000 shares of common stock, exercisable for a period of five years at $0.333 per share, with one-third of the options (66,666 shares) vesting immediately upon joining the Board and one-third vesting annually on each of June 30, 2007 and 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $62,000 ($0.31 per share), of which $20,666 was charged to operations on June 30, 2006, and the remaining $41,334 was charged to operations ratably from July 1, 2006 through June 30, 2008. On June 30, 2011, these options to acquire 200,000 shares of common stock expired unexercised.
	On June 30, 2006, effective with the closing of the Exchange, the Company also granted to Dr. Palmedo additional stock options to purchase 190,000 shares of common stock exercisable for a period of five years at $0.333 per share for services rendered in developing the business plan for Lixte, all of which were fully vested upon issuance. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $58,900 ($0.31 per share), and was charged to operations at June 30, 2006. On June 30, 2011, Dr. Palmedo exercised options to acquire 100,000 shares of common stock, which were part of this grant, on a cashless basis. Such cashless exercise resulted in Dr. Palmedo receiving a net of 66,020 shares of common stock. The remaining options to acquire 290,000 shares of common stock, which were also a part of this grant, expired unexercised on June 30, 2011.
	On June 30, 2011, the Company granted to Dr. Palmedo stock options to purchase 200,000 shares of common stock, exercisable for a period of five years from the date of grant at $0.98 per share, which was the fair market value of the Company’s common stock on such date. The options vest ratably in equal quarterly installments of 25,000 shares beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $196,000 ($0.98 per share). During the years ended December 31, 2013 and 2012, the Company recorded charges to operations of $48,530 and $98,134, respectively, with respect to these options.
	On June 30, 2006, effective with the closing of the Exchange, the Company granted to Dr. Stefan Madajewicz and Dr. Iwao Ojima, two members of its Scientific Advisory Committee, stock options to purchase an aggregate of 100,000 shares of common stock (50,000 each) exercisable for a period of five years at $0.333 per share, with one-half of the options vesting annually on each of June 30, 2007 and June 30, 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was charged to operations ratably from July 1, 2006 through June 30, 2008.
	In August 2008, Dr. Madajewicz resigned from his position and waived his right to his vested stock option to purchase 50,000 shares of common stock.
	On June 30, 2011, Dr. Ojima exercised options to acquire 15,015 shares of common stock for a cash payment of $5,000. Dr. Ojima’s remaining options to acquire 34,985 shares of common stock expired unexercised.
	On June 30, 2011, the Company granted to Dr. Ojima stock options to purchase 50,000 shares of common stock, exercisable for a period of five years from the date of grant at $0.98 per share, which was the fair market value of the Company’s common stock on such date. The options vest ratably in equal quarterly installments of 6,250 shares beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $49,000 ($0.98 per share). During the years ended December 31, 2013 and 2012, the Company recorded a charge (credit) to operations of $3,357 and $(650), respectively, with respect to these options.
	On February 5, 2007, the Company entered into an agreement (the “Chem-Master Agreement”) with Chem-Master International, Inc. (“Chem-Master”), a company co-owned by Francis Johnson, a consultant to the Company, pursuant to which the Company granted a five-year option to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.333 per share. The fair value of this option, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $31,000 ($0.31 per share) which was charged to operations as research and development costs on February 5, 2007 as the option was fully vested and non-forfeitable on the date of issuance. The Company has the right to terminate the Chem-Master Agreement at any time during its term upon sixty days prior written notice. On February 5, 2009, provided that the Chem-Master Agreement had not been terminated prior to such date, the Company agreed to grant Chem-Master a second five-year option to purchase an additional 100,000 shares of the Company’s common stock at an exercise price of $0.333 per share. As of September 30, 2008, the Company determined that it was likely that this option would be issued. Accordingly, the fair value of the option was reflected as a charge to operations for the period from October 1, 2008 through February 5, 2009. The Company granted the second five-year option on February 5, 2009. On February 4, 2012, Chem-Master exercised the option to acquire 100,000 shares of common stock previously granted on February 5, 2007 for a cash payment of $33,333.
	On January 29, 2008, the Chem-Master Agreement was amended to extend its term to February 15, 2014. Pursuant to the amendment, the Company issued 100,000 shares of its restricted common stock and granted an option to purchase 200,000 shares of common stock. The option was exercisable for a period of two years from the vesting date at $1.65 per share, with one-half (100,000 shares) vesting on August 1, 2009, and one-half (100,000 shares) vesting on February 1, 2011. The restricted common stock issued, which was valued at $75,000, was charged to operations as research and development costs on January 29, 2008. The initial fair value of the option, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $96,000 ($0.48 per share) and was charged to operations ratably during the period from February 1, 2008 through February 1, 2011. On August 1, 2011, the option to acquire 100,000 shares of common stock that vested on August 1, 2009 expired unexercised. On February 1, 2013, the option to acquire the remaining 100,000 shares of common stock that vested on February 1, 2011 also expired unexercised.
	On September 11, 2012, the Company granted to Chem-Master a stock option to purchase 500,000 shares of common stock, exercisable for a period of five years from the date of grant at $0.65 per share, which was the fair market value of the Company’s common stock on such date. The fair value of this option, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $293,450 ($0.59 per share), which was charged to operations as research and development costs on September 11, 2012, as the option was fully vested and non-forfeitable on the date of issuance. The option includes cashless exercise provisions.
	On June 20, 2007, the Board of Directors of the Company approved the 2007 Stock Compensation Plan (the “2007 Plan”), which provides for the granting of awards, consisting of common stock options, stock appreciation rights, performance shares, or restricted shares of common stock, to employees and independent contractors, for up to 2,500,000 shares of the Company’s common stock, under terms and condition, as determined by the Company’s Board of Directors.
	On September 12, 2007, in conjunction with his appointment as a director of the Company, the Company granted to Dr. Stephen Carter stock options to purchase an aggregate of 200,000 shares of common stock under the 2007 Plan, exercisable for a period of five years from vesting date at $0.333 per share, with one-half (100,000 shares) vesting annually on each of September 12, 2008 and 2009. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $204,000 ($1.02 per share), and was charged to operations ratably from September 12, 2007 through September 12, 2009. Effective April 20, 2010, Dr. Carter resigned as a director for personal reasons. Consequently, pursuant to the stock option agreement, Dr. Carter had twelve months from April 20, 2010 to exercise his stock options to acquire 200,000 shares of the Company’s common stock. On April 20, 2011, Dr. Carter’s stock options expired unexercised.
	On September 12, 2007, the Company entered into a consulting agreement with Gil Schwartzberg, pursuant to which the Company granted to Mr. Schwartzberg stock options to purchase an aggregate of 1,000,000 shares of common stock, exercisable for a period of the earlier of four years from the vesting date or the termination of the consulting agreement at $1.00 per share, with one-half of the options (500,000 shares) vesting immediately and one-half of the options (500,000 shares) vesting on September 12, 2008. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $945,000 ($0.945 per share), of which $465,000 was attributed to the fully-vested options and was thus charged to operations on September 12, 2007. The remaining unvested portion of the fair value of the options was charged to operations ratably from September 12, 2007 through September 12, 2008. On September 12, 2011, options to acquire 500,000 shares of common stock expired unexercised. On September 12, 2012, options to acquire the remaining 500,000 shares of common stock expired unexercised.
	On October 15, 2009, the Company approved a first amendment to the above described consulting agreement with Gil Schwartzberg to extend it for an additional four years and granted to Mr. Schwartzberg stock options to purchase an additional aggregate of 1,000,000 shares of common stock, exercisable for a period of the earlier of four years from the vesting date or the termination of the consulting agreement at $1.00 per share, with one-half of the options (500,000 shares) vesting immediately and one-half (500,000 shares) vesting on October 15, 2010. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $750,000 ($0.75 per share) on October 15, 2009, of which $375,000 was attributed to the fully-vested options and was thus charged to operations on October 15, 2009. The remaining unvested portion of the fair value of the options was charged to operations ratably from October 15, 2009 through October 15, 2010. On October 15, 2013, options to acquire 500,000 shares of common stock expired unexercised.
	On January 28, 2014, the Company entered into a second amendment to the Company’s consulting agreement with Gil Schwartzberg, a consultant and significant shareholder of the Company, as described at Note 9.
	On October 5, 2011, the Company granted to Mr. Schwartzberg stock options to purchase an aggregate of 500,000 shares of common stock, exercisable for a period of the earlier of five years from the grant date or the termination of the consulting agreement at $1.00 per share. One-quarter of the options vested immediately, with the balance vesting in three equal quarterly installments beginning on January 5, 2012. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $325,000 ($0.65 per share) and was charged to operations ratably from October 5, 2011 through October 4, 2012. During the year ended December 31, 2012, the Company recorded a charge to operations of $210,410 with respect to these options.
	On September 11, 2012, the Company granted to Mr. Schwartzberg stock options to purchase 500,000 shares of common stock, exercisable for a period of the earlier of five years from the date of grant or the termination of the consulting agreement at $1.00 per share, which was the fair market value of the Company’s common stock on such date. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $286,100 ($0.57 per share), which was charged to operations on September 11, 2012, as the options were fully vested and non-forfeitable on the date of issuance.
	On September 12, 2007, the Company entered into a consulting agreement with Francis Johnson, a co-owner of Chem-Master International, Inc., and granted to Professor Johnson stock options to purchase an aggregate of 300,000 shares of common stock, exercisable for a period of four years from the vesting date at $0.333 per share, with one-third (100,000 shares) vesting annually on each of September 12, 2008, 2009 and 2010. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $300,000 ($1.00 per share). The unvested portion of the fair value of the options was charged to operations from September 12, 2007 through September 12, 2010. On September 12, 2013 and 2012, options to acquire 100,000 shares expired unexercised.
	On September 20, 2007, the Company entered into a one-year consulting agreement (the “Mirador Agreement”) with Mirador Consulting, Inc. (“Mirador”), pursuant to which Mirador was to provide the Company with various financial services. Pursuant to the Mirador Agreement, the Company agreed to pay Mirador $5,000 per month and also agreed to sell Mirador 250,000 shares of the Company’s restricted common stock for $250 ($0.001 per share). The fair value of this transaction was determined to be in excess of the purchase price by $262,250 ($1.049 per share), reflecting the difference between the $0.001 purchase price and the $1.05 price per share as quoted on the OTC Bulletin Board on the transaction date, and was charged to operations as stock-based compensation on September 20, 2007, since the shares were fully vested and non-forfeitable on the date of issuance.
	On October 7, 2008, the Company appointed Dr. Mel Sorensen to its Board of Directors. Dr. Sorensen was paid an annual consulting fee of $40,000, payable in quarterly installments over a one year period commencing October 7, 2008, to assist the Company in identifying a strategic partner. Dr. Sorensen was also granted a stock option to purchase 200,000 shares of the Company’s common stock, exercisable at $0.50 per share for a period of five years from each tranche’s vesting date. The option vested as to 25,000 shares on January 1, 2009, and a further 25,000 shares vested on the first day of each subsequent calendar quarter until all of the shares were vested. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $100,000 ($0.50 per share), and was charged to operations ratably from October 7, 2008 through October 7, 2010.
	Effective May 1, 2011, in connection with his election to the Company’s Board of Directors, Dr. Robert B. Royds was granted stock options to purchase 200,000 shares of the Company’s common stock, vesting 25,000 shares on May 1, 2011, and 25,000 shares quarterly thereafter until all of the shares are vested, exercisable for a period of five years from each tranche’s vesting date, at $0.98 per share, which was the fair market value of the Company’s common stock on such date. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $196,000 ($0.98 per share), and was charged to operations ratably from May 2, 2011 through February 1, 2013. During the year ended December 31, 2013 and 2012, the Company recorded charges to operations of $8,548 and $97,770, respectively, with respect to these options. Dr. Royds died on March 23, 2013. As a result of the death of Dr. Royds, pursuant to the stock option agreement, Dr. Royds' executor has twelve months from March 23, 2013 to exercise his stock options to acquire 200,000 shares of the Company’s common stock.
	Effective September 16, 2012, in connection with her election to the Company’s Board of Directors, Dr. Kathleen P. Mullinix was granted stock options to purchase 200,000 shares of the Company’s common stock, vesting 25,000 shares on September 16, 2012, and 25,000 shares quarterly thereafter until all of the shares are vested, exercisable for a period of five years from the date of grant at $0.65 per share, which was the fair market value of the Company’s common stock on such date. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $118,000 ($0.59 per share), and is being charged to operations from September 16, 2012 through June 16, 2014. During the years ended December 31, 2013 and 2012, the Company recorded charges to operations of $58,690 and $31,790, respectively, with respect to these options.
	On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. ("NDA") for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company's Scientific Advisory Committee.  In connection with this agreement, NDA was granted stock options to purchase 100,000 shares of the Company’s common stock, vesting 25,000 shares on June 24, 2014, and thereafter 25,000 shares annually on June 24, 2015, 2016 and 2017, exercisable for a period of five years from the date of grant at $0.13 per share, which was the fair market value of the Company’s common stock on the grant  date. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $12,960 ($0.13 per share), and is being charged to operations from December 24, 2013 through June 24, 2017. During the year ended December 31, 2013, the Company recorded a charge to operations of $125 with respect to these options.
	If and when the aforementioned stock options are exercised, the Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.
	A summary of stock option activity is presented in the tables below.
									Weighted
									Average
						Weighted			Remaining
			Number			Average			Contractual
			of			Exercise			Life
			Shares			Price			(in Years)
	Options outstanding at December 31, 2011			3,250,000		$	0.884
	Granted			1,200,000			0.796
	Exercised			-100,000			0.333
	Expired			-600,000			0.889
	Options outstanding at December 31, 2012			3,750,000			0.87
	Granted			100,000			0.13
	Exercised			—			—
	Expired			-700,000			1.045
	Options outstanding at December 31, 2013			3,150,000		$	0.818			2.62
	Options exercisable at December 31, 2012			3,512,500		$	0.876
	Options exercisable at December 31, 2013			3,000,000		$	0.843			2.52
	Total deferred compensation expense for the outstanding value of unvested stock options was approximately $40,000 at December 31, 2013, which is being recognized subsequent to December 31, 2013 over a weighted-average period of approximately seventeen months.
	The exercise prices of common stock options outstanding and exercisable are as follows at December 31, 2013:
				Options			Options
	Exercise			Outstanding			Exercisable
	Prices			(Shares)			(Shares)
	$	0.13			100,000			—
	$	0.333			200,000			200,000
	$	0.5			200,000			200,000
	$	0.65			700,000			650,000
	$	0.98			450,000			450,000
	$	1			1,500,000			1,500,000
					3,150,000			3,000,000
	Based on a fair market value of $0.13 per share on December 31, 2013, there were no exercisable but unexercised in-the-money common stock options on that date. Accordingly, there was no intrinsic value attributed to exercisable but unexercised common stock warrants at December 31, 2013.
	Based on a fair market value of $0.25 per share on December 31, 2012, there were no exercisable but unexercised in-the-money stock options on that date. Accordingly, there was no intrinsic value attributed to exercisable but unexercised stock options at December 31, 2012.
	Outstanding options to acquire 150,000 shares of the Company’s common stock had not vested at December 31, 2013.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	7. Income Taxes
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets as of December 31, 2013 and 2012 are summarized below.
			December 31,
			2013			2012
	Start-up and organization costs		$	56,000		$	63,000
	Research credits			95,000			68,000
	Contingent liability			31,000			31,000
	Net operating loss carryforwards			2,939,000			2,421,000
	Total deferred tax assets			3,121,000			2,583,000
	Valuation allowance			-3,121,000			-2,583,000
	Net deferred tax assets		$	—		$	—
	In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2013 and 2012, management was unable to determine if it is more likely than not that the Company’s deferred tax assets will be realized, and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates.
	No federal tax provision has been provided for the years ended December 31, 2013 and 2012 due to the losses incurred during such periods. Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rate for the years ended December 31, 2013 and 2012.
			Years Ended
			December 31,
		2012				2012
	U. S. federal statutory tax rate			-34	%			-34	%
	Non-deductible stock-based compensation			2.9	%			8.6	%
	Non-deductible fair value of warrant extensions			—	%			10.8	%
	Non-deductible fair value of warrant discounts			—	%			3.2	%
	Adjustment to deferred tax asset			-1.3	%			-2	%
	Change in valuation allowance			32.4	%			13.4	%
	Effective tax rate			0	%			0	%
	At December 31, 2013, the Company has available net operating loss carryforwards for federal income tax purposes of approximately $7,099,000 which, if not utilized earlier, expire through 2032.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	8.  Commitments and Contingencies
	Cooperative Research and Development Agreement (CRADA)
	Effective March 22, 2006, the Company entered into a CRADA with the NINDS of the NIH. The CRADA was extended through a series of amendments and remained in effect until April 1, 2013. The CRADA provided for the collaboration between the parties in the identification and evaluation of agents that target the Nuclear Receptor CoRepressor (N-CoR) pathway for glioma cell differentiation. The CRADA also provided that NINDS and the Company would conduct research to determine if expression of N-CoR correlates with prognosis in glioma patients. Pursuant to the CRADA, the Company initially agreed to provide funds under the CRADA in the amount of $200,000 per year to fund two technical assistants for the technical, statistical and administrative support for the research activities, as well as to pay for supplies and travel expenses. The first $200,000 was due within 180 days of the effective date and was paid in full on July 6, 2006. The second $200,000 was paid in full on June 29, 2007. In June 2008, the CRADA was extended to September 30, 2009, with no additional funding required for the period between July 1, 2008 and September 30, 2008. For the period from October 1, 2008 through September 30, 2009, the Company agreed to provide additional funding under the CRADA of $200,000, to be paid in four quarterly installments of $50,000, each commencing on October 1, 2008. The first and second quarterly installments of $50,000 were paid on September 29, 2008 and March 5, 2009, respectively. During August 2009, the Company entered into an amendment to the CRADA to extend its term from September 30, 2009 through September 30, 2011. Pursuant to such amendment, the Company agreed to aggregate payments of $100,000 in two installments of $50,000, payable on October 1, 2010 and January 5, 2011, inclusive of any prior unpaid commitments. The October 1, 2010 installment was paid on September 29, 2010 and the January 5, 2011 installment was paid on December 27, 2010. In September 2011, the CRADA was amended to extend its term to June 1, 2012 and to provide additional funding of $50,000, payable in two installments of $25,000 each on October 1, 2011 and February 5, 2012. The October 1, 2011 installment was paid on October 12, 2011, and by mutual agreement, the February 5, 2012 installment was paid on May 1, 2012. In August 2012, the CRADA was extended to April 1, 2013, with no additional funding requirement. The CRADA terminated as scheduled on April 1, 2013.
	Patent License Agreement
	Effective September 19, 2008, the Company entered into a Patent License Agreement (the “PLA”) with the NIH providing the Company with an exclusive license for all patents submitted jointly with the NIH under the CRADA. The PLA provided for an initial payment of $25,000 to the NIH within 60 days of September 19, 2008, and for a minimum annual royalty of $30,000 on January 1 of each calendar year following the year in which the CRADA is terminated. The PLA also provided for the Company to pay (i) specified royalties based on net sales by the Company and its sub-licensees, reduced by the amount of the minimum annual royalty for that year, (ii) certain benchmark royalties upon the achievement of certain clinical benchmarks, and (iii) sublicensing royalties for the granting of sublicenses, with respect to joint patents. The Company paid the initial $25,000 obligation on November 10, 2008, which was charged to general and administrative costs. As of December 31, 2013 and 2012, no amounts were due pursuant to the PLA. Due to the termination of the CRADA on April 1, 2013, the Company currently expects to pay a minimum annual royalty of $30,000 to the NIH beginning in 2014 and each year thereafter.
	Materials Cooperative Research and Development Agreement (M-CRADA)
	Effective October 18, 2013, the Company entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NINDS, NIH) for a term of four years.  The Surgical Neurology Branch of NINDS, NIH will conduct research characterizing a variety of compounds proprietary to the Company, and will examine the compounds’ potential for anti-cancer activity, reducing neurological deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases.  Under an M-CRADA, a party provides research material, in this case proprietary compounds from the Company’s pipeline, for study by scientists at NIH.  The exchange of material is for research only and implies no endorsement of the material on the part of either party.  Under the M-CRADA the NIH grants a collaborator an exclusive option to elect an exclusive or non-exclusive commercialization license. The M-CRADA does not generate any incremental cost to the Company.
	Research and Development Contracts
	On February 5, 2007, the Company entered into a two-year agreement pursuant to which the Company engaged Chem-Master to synthesize a compound designated as LB-100, and any other compound synthesized by Chem-Master pursuant to the Company’s request, which have potential use in treating a disease, including, without limitation, cancers such as glioblastomas. Pursuant to the Chem-Master Agreement, the Company agreed to reimburse Chem-Master for the cost of materials, labor, and expenses for other items used in the synthesis process, and also agreed to grant Chem-Master a five-year option to purchase shares of the Company’s common stock.  On January 29, 2008, the Chem-Master Agreement was amended to extend its term to February 15, 2014; thereafter, Chem-Master will be engaged as needed. The Company also periodically enters into other agreements with Chem-Master for other services. During the years ended December 31, 2013 and 2012, the Company recorded charges to operations of $7,275 and $24,500, respectively, with respect to this agreement.
	On September 21, 2012, the Company entered into a work order agreement with Theradex to manage and administer the Phase 1 clinical trial of LB-100. Theradex is an international CRO that provides professional services for the clinical research and development of pharmaceutical compounds. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed within the next 12 to 21 months (sometime between March and December 2015). The Phase 1 clinical trial is estimated to cost a total of approximately $2,000,000, with such payments expected to be divided approximately evenly between payments to Theradex for services rendered and payments for pass-through costs for the clinical center’s laboratory costs and investigator costs. Total costs charged to operations for services paid to Theradex pursuant to this arrangement, which were first incurred in 2013, were $278,721 for the year ended December 31, 2013. Costs pursuant to this agreement are included in research and development costs in the Company's consolidated statements of operations. On May 2, 2011, Dr. Robert B. Royds, the founder, Chairman of the Board and Medical Director of Theradex, was appointed to the Company’s Board of Directors. Dr. Royds died on March 23, 2013. The death of Dr. Royds is not expected to have any impact on the management and administration of the Phase 1 clinical trial.
	In addition to the above described agreement with Theradex, the Company has also from time to time engaged Theradex to assist the Company in bringing LB-100 through the FDA approval process and to provide other services. Total fees charged to operations for services paid to Theradex pursuant to such engagements were $14,964 and $163,661 for the years ended December 31, 2013 and 2012, respectively, and $194,551 for the period from August 9, 2005 (inception) to December 31, 2013 (cumulative), and are included in research and development costs in the Company's consolidated statements of operations.
	Periodically, the Company has entered into agreements with Ascentage Pharma Group to conduct various studies. As of December 31, 2013, contracts with a total estimated cost of $29,025, of which $17,415 had been paid, were in process. Ascentage Pharma Group is an offshoot of Ascenta Therapeutics, of which Dr. Mel Sorensen, a director of the Company, is the President and Chief Executive Officer and a director. Ascentage Pharma Group and Ascenta Therapeutics have a continuing business relationship and certain common shareholders. However, Dr. Sorensen does not have any direct business relationship with or ownership in Ascentage Pharma Group.
	At various times, the Company has entered into agreements with other unrelated vendors to conduct certain required studies. As of December 31, 2013, contracts outstanding with such vendors and in currently process had a total estimated cost of $104,100, of which $75,325 had been paid.
	Consulting Agreement
	On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. ("NDA") for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company's Scientific Advisory Committee. The term of the agreement is for one year and provides for a quarterly cash fee of $4,000. The first such quarterly cash payment was made on January 12, 2014. There were no consulting or advisory fees charged to operations  prior to January 1, 2014.   In connection with this agreement, NDA was granted stock options to purchase   100,000 shares of the Company’s common stock, vesting 25,000 shares on June 24, 2014, and thereafter 25,000 shares annually on June 24, 2015, 2016 and 2017, exercisable for a period of five years from the date of grant at $0.13 per share.
	The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of December 31, 2013 aggregating $ 2,119,565, of which $213,000 is included in current liabilities in the consolidated balance sheet at December 31, 2013.
				Payments Due By Year
		Total		2014		2015		2016		2017		2018
	Research and development contracts	$	40,385	$	40,385	$	—	$	—	$	—	$	—
	Theradex work order agreement		1,746,463		1,346,463		400,000		—		—		—
	Patent license agreement		150,000		30,000		30,000		30,000		30,000		30,000
	Consulting agreement		16,000		16,000		—		—		—		—
	Liquidated damages payable under registration rights agreement		74,000		74,000		—		—		—		—
	Due to stockholder		92,717		92,717		—		—		—		—
	Total	$	2,119,565	$	1,599,565	$	430,000	$	30,000	$	30,000	$	30,000

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	9. Subsequent Events
	Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company, effective for an initial term of one year through December 31, 2014 to advise on business development matters.  The initial term and any subsequent one year term shall be automatically extended on an annual basis unless a notice of intent to terminate is given by either party at least 90 days before the end of the applicable term.  The Advisory Agreements provides for compensation of $25,000 annually, payable in two installments of $12,500, with the first payment due on January 31, 2014 and the second payment due on July 1, 2014.
	On January 28, 2014, the Company approved a second amendment to the Company’s consulting agreement with Gil Schwartzberg to extend it to January 28, 2019 and granted to Mr. Schwartzberg stock options to purchase an additional aggregate of 4,000,000 shares of common stock, exercisable for a period of the earlier of five years from the grant date or the termination of the consulting agreement at $0.50 per share, with one-half of the options (2,000,000 shares) vesting immediately and one-half (2,000,000 shares) vesting on January 28, 2015. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $596,400 ($0.15 per share) on January 28, 2014, of which $298,200 is attributed to the options fully-vested on January 28, 2014 and as such will be charged to operations on that date. The remaining unvested portion of the fair value of the options will be charged to operations ratably from January 28, 2014 through January 28, 2015.
	On January 28, 2014, the Company’s Board of Directors extended to June 30, 2014 its outstanding warrants to acquire 1,748,800 shares of the Company’s common stock exercisable at $0.50 per share that were issued to investors and placement agent in connection with private placements that closed on February 10, 2009, March 2, 2009 and April 6, 2009. On September 30, 2012, the Company had previously extended all other outstanding warrants to June 30, 2014. Included in the January 2014 extension were warrants to acquire 815,920 shares of common stock scheduled to expire on February 10, 2014, warrants to acquire 312,880 shares of common stock scheduled to expire on March 2, 2014, and warrants to acquire 620,000 shares of common stock scheduled to expire on April 6, 2014. The fair value of the warrant extensions, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $78,617 (average of $0.04 per share), and such amount will be charged to operations on January 28, 2014. The fair value of the warrant extensions were calculated using the following input variables: stock price - $0.15 per share; exercise price - $0.50 per share; expected life – 13 to 153 days; expected volatility – 262%; expected dividend yield - 0%; risk-free interest rate – 1.51%.
	On January 28, 2014, the Company offered to all of its warrant holders an inducement to exercise early by reducing the exercise price of currently outstanding warrants by  50%, if exercised on a cash basis by April 15, 2014. The exercise prices of the warrants before reduction were $0.50 per share (2,253,800 warrants) and $0.75 per share (4,575,000 warrants). The aggregate fair value of the warrant discounts, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $134,420 (an average of $0.02 per share), and such amount will be charged to operations on January 28, 2014. The fair value of the warrant extensions were calculated using the following input variables: stock price - $0.15 per share; exercise price - $0.50 and $0.75 per share; expected life – 77 days (the period during which the discount was available); expected volatility – 262%; expected dividend yield - 0%; risk-free interest rate – 1.51%.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The accompanying consolidated financial statements include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. All intercompany balances and transactions have been eliminated in consolidation.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash Concentrations
	The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates.
	Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s balance sheet and then charged to research and development costs in the Company’s statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s balance sheet, with a corresponding charge to research and development costs in the Company’s statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.
Patent Costs [Policy Text Block]	'
	Patent Costs
	Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company's research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $405,285 and $236,784 for the years ended December 31, 2013 and 2012, respectively, and $1,814,682 for the period from August 9, 2005 (inception) to December 31, 2013 (cumulative). Patent costs are included in research and development costs in the Company's consolidated statements of operations.
Royalties Policy [Policy Text Block]	'
	Royalties
	Pursuant to a Patent License Agreement with the NIH that provides the Company with an exclusive license for all patents submitted jointly with the NIH under the CRADA, various categories of royalties at various rates and amounts are payable, including minimum annual royalties (subject to an offset for royalties from net sales), royalties on net sales, royalties based on the achievement of certain benchmarks, and royalties based on granting sublicense agreements, with respect to joint patents. Such royalties are accrued and paid when they become legal obligations, and are charged to general and administrative costs.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Risk
	The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task, and can include both cash and non-cash compensation.  The only such contract that represents 10% or more of general and administrative or research and development costs is described below.
	On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. Theradex is an international CRO that provides professional services for the clinical research and development of pharmaceutical compounds. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed within the next 12 to 21 months (sometime between March and December 2015). The Phase 1 clinical trial is expected to cost a total of approximately $2,000,000, with such payments expected to be divided approximately evenly between payments to Theradex for services rendered and payments for pass-through costs for the clinical center’s laboratory costs and investigator costs. Total costs charged to operations for services paid to Theradex pursuant to this arrangement, which were first incurred in 2013, were $278,721 for the year ended December 31, 2013, or approximately 32% of research and development costs for the year ended December 31, 2013. The costs charged to operations for amounts paid to Theradex for services relating to the Phase 1 clinical trial of LB-100 are expected to represent a larger percentage of total research and development costs during the fiscal years ending December 31, 2014 and 2015. Costs pursuant to this agreement are included in research and development costs in the Company's consolidated statements of operations. On May 2, 2011, Dr. Robert B. Royds, the founder, Chairman of the Board and Medical Director of Theradex, was appointed to the Company’s Board of Directors. Dr. Royds died on March 23, 2013. The death of Dr. Royds is not expected to have any impact on the management and administration of the Phase 1 clinical trial.
	In addition to the above described agreement with Theradex, the Company has also from time to time engaged Theradex to assist the Company in bringing LB-100 through the FDA approval process and to provide other services. Total fees charged to operations for services paid to Theradex pursuant to such engagements were $14,964 and $163,661 for the years ended December 31, 2013 and 2012, respectively, or approximately 2% and 16% of research and development costs for the years ended December 31, 2013 and 2012, respectively, and are included in research and development costs in the Company's consolidated statements of operations.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.
	The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period.
	The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.
	For federal income tax purposes, net operating losses can be carried forward for a period of 20 years until they are either utilized or until they expire.
	On January 1, 2007, the Company adopted accounting rules which address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under these rules, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. These accounting rules also provide guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of December 31, 2013, no liability for unrecognized tax benefits was required to be recorded.
	The Company files income tax returns in the U.S. federal jurisdiction and is subject to income tax examinations by federal tax authorities for the year 2009 and thereafter. The Company’s policy is to record interest and penalties on uncertain tax provisions as income tax expense. As of December 31, 2013, the Company has no accrued interest or penalties related to uncertain tax positions.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	The Company periodically issues stock options and warrants to officers, directors and consultants for services rendered. Options vest and expire according to terms established at the grant date.
	The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in the Company’s financial statements on a straight-line basis over the vesting period of the awards.
	The Company accounts for stock-based payments to consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.
	Options granted to members of the Company’s Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings Per Share
	The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.
	Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive.
	At December 31, 2013 and 2012, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.
		2013		2012
	Warrants		6,828,800		6,828,800
	Stock options		3,150,000		3,750,000
	Total		9,978,800		10,578,800
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The carrying amounts of cash, money market funds, advances on research and development contract services, prepaid expenses and other current assets, accounts payable and accrued expenses, research and development contract liabilities, liquidated damages payable under registration rights agreement and due to stockholder approximate their respective fair values due to the short-term nature of these items.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2013-04, Liabilities (Topic 405): Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date.  This guidance provides direction for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this guidance is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. This guidance will become effective for the Company for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s consolidated financial statements.
	In March 2013, the FASB issued ASU No. 2013-05, Foreign Currency Matters (Topic 830). This guidance resolves the diversity in practice relating to financial reporting involving a parent entity’s accounting for the cumulative translation adjustment of foreign currency into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, this guidance resolves the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. This guidance will become effective for the Company for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s consolidated financial statements.
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Loss, or a Tax Credit Carryforward Exists (a consensus the FASB Emerging Issues Task Force). This guidance provides direction on financial statement presentation of unrecognized tax benefit when a net operating loss carrforward, a similar tax loss, or a tax credit carryforward exists. The FASB’s objective in issuing this guidance was to eliminate diversity in practice resulting from a lack of guidance on this topic in current U.S. GAAP. This guidance applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date. This guidance will become effective for the Company for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s consolidated financial statements.
	Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	At December 31, 2013 and 2012, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.
		2013		2012
	Warrants		6,828,800		6,828,800
	Stock options		3,150,000		3,750,000
	Total		9,978,800		10,578,800

Share_Exchange_Agreement_Priva1

Share Exchange Agreement, Private Placements and Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2013
Share Exchange Agreement Private Placements and Common Stock Warrants [Abstract]	'
Schedule Of Activity Of Warrants Issued Primarily In Connection With Financing [Table Text Block]	'
	A summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s private placements, is presented in the tables below. For presentation purposes, warrants that were extended are considered as outstanding for the entire period in which such extension occurs.
							Weighted
							Average
					Weighted		Remaining
			Number		Average		Contractual
			of		Exercise		Life
			Shares		Price		(in Years)
	Warrants outstanding at December 31, 2011			13,454,552	$	0.607
	Issued			—		—
	Exercised			-6,355,752		0.535
	Expired			-270,000		0.844
	Warrants outstanding at December 31, 2012			6,828,800		0.667
	Issued			—		—
	Exercised			—		—
	Expired			—		—
	Warrants outstanding at December 31, 2013			6,828,800	$	0.667		0.67
	Warrants exercisable at December 31, 2012			6,659,840	$	0.672
	Warrants exercisable at December 31, 2013			6,659,840	$	0.672		0.42
Schedule Of Shares Authorized Under Stock Warrants By Exercise Price Range [Table Text Block]	'
	The exercise prices of common stock warrants outstanding and exercisable are as follows at December 31, 2013:
				Warrants	Warrants
	Exercise			Outstanding	Exercisable
	Prices			(Shares)	(Shares)
	$	0.5		2,253,800	2,084,840
	$	0.75		4,575,000	4,575,000
				6,828,800	6,659,840

Money_Market_Funds_Fair_Value_

Money Market Funds - Fair Value (Tables)	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
	The following table presents money market funds at their level within the fair value hierarchy at December 31, 2013 and 2012.
		Total		Level 1		Level 2		Level 3
	December 31, 2013:
	Money market funds	$	6,135	$	6,135	$	—	$	—
	December 31, 2012:
	Money market funds	$	6,134	$	6,134	$	—	$	—

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Share-Based Compensation [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of stock option activity is presented in the tables below.
									Weighted
									Average
						Weighted			Remaining
			Number			Average			Contractual
			of			Exercise			Life
			Shares			Price			(in Years)
	Options outstanding at December 31, 2011			3,250,000		$	0.884
	Granted			1,200,000			0.796
	Exercised			-100,000			0.333
	Expired			-600,000			0.889
	Options outstanding at December 31, 2012			3,750,000			0.87
	Granted			100,000			0.13
	Exercised			—			—
	Expired			-700,000			1.045
	Options outstanding at December 31, 2013			3,150,000		$	0.818			2.62
	Options exercisable at December 31, 2012			3,512,500		$	0.876
	Options exercisable at December 31, 2013			3,000,000		$	0.843			2.52
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	The exercise prices of common stock options outstanding and exercisable are as follows at December 31, 2013:
				Options			Options
	Exercise			Outstanding			Exercisable
	Prices			(Shares)			(Shares)
	$	0.13			100,000			—
	$	0.333			200,000			200,000
	$	0.5			200,000			200,000
	$	0.65			700,000			650,000
	$	0.98			450,000			450,000
	$	1			1,500,000			1,500,000
					3,150,000			3,000,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Significant components of the Company's deferred tax assets as of December 31, 2013 and 2012 are summarized below.
			December 31,
			2013			2012
	Start-up and organization costs		$	56,000		$	63,000
	Research credits			95,000			68,000
	Contingent liability			31,000			31,000
	Net operating loss carryforwards			2,939,000			2,421,000
	Total deferred tax assets			3,121,000			2,583,000
	Valuation allowance			-3,121,000			-2,583,000
	Net deferred tax assets		$	—		$	—
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rate for the years ended December 31, 2013 and 2012.
			Years Ended
			December 31,
		2012				2012
	U. S. federal statutory tax rate			-34	%			-34	%
	Non-deductible stock-based compensation			2.9	%			8.6	%
	Non-deductible fair value of warrant extensions			—	%			10.8	%
	Non-deductible fair value of warrant discounts			—	%			3.2	%
	Adjustment to deferred tax asset			-1.3	%			-2	%
	Change in valuation allowance			32.4	%			13.4	%
	Effective tax rate			0	%			0	%

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule Of Principal Cash Obligations and Commitments [Table Text Block]	'
	The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of December 31, 2013 aggregating $ 2,119,565, of which $213,000 is included in current liabilities in the consolidated balance sheet at December 31, 2013.
				Payments Due By Year
		Total		2014		2015		2016		2017		2018
	Research and development contracts	$	40,385	$	40,385	$	—	$	—	$	—	$	—
	Theradex work order agreement		1,746,463		1,346,463		400,000		—		—		—
	Patent license agreement		150,000		30,000		30,000		30,000		30,000		30,000
	Consulting agreement		16,000		16,000		—		—		—		—
	Liquidated damages payable under registration rights agreement		74,000		74,000		—		—		—		—
	Due to stockholder		92,717		92,717		—		—		—		—
	Total	$	2,119,565	$	1,599,565	$	430,000	$	30,000	$	30,000	$	30,000

Organization_and_Business_Oper1

Organization and Business Operations (Details Textual) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
	Jun. 30, 2006	Apr. 30, 2013	Dec. 31, 2013
Organization And Business Operations [Line Items]	'	'	'
Proceeds from Related Party Debt	$92,717	'	'
Estimated Cost Of Clinical Trial Lab	'	2,000,000	'
Cost Of Clinical Trial Lab	'	'	278,721
Cash And Money Market Funds	'	'	$481,154

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,978,800	10,578,800
Warrants [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,828,800	6,828,800
Stock options [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,150,000	3,750,000

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended		101 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Sep. 21, 2012
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Research and Development Expense	$879,886	$1,012,144	$5,449,678	'
Deferred Setup and Organization Costs, Amortization Period (in months)	'180 months	'	'	'
Deferred Setup and Organization Costs, Amortization Period (in Years)	'20 years	'	'	'
Clinical Research And Development Cost Percentage	32.00%	16.00%	'	'
Fees For Services Total	14,964	163,661	'	'
Agreement With Theradex Systems [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Annual Fee Payable, Clinical Trial	'	'	'	2,000,000
Clinical Cost Charged To Operations Total	278,721	'	'	'
Clinical Research And Development Cost Percentage	2.00%	'	'	'
Fees For Services Total	14,964	163,661	194,551	'
Patents [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Research and Development Expense	$405,285	$236,784	$1,814,682	'

Share_Exchange_Agreement_Priva2

Share Exchange Agreement, Private Placements and Common Stock Warrants (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share Exchange Agreement Private Placement And Common Stock Warrants [Line Items]	'	'
Beginning Balance - Warrants outstanding, Number of Shares (in shares)	6,828,800	13,454,552
Warrants Issued, Number of Shares (in shares)	0	0
Warrants Exercised, Number of Shares (in shares)	0	-6,355,752
Warrants Expired, Number of Shares (in shares)	0	-270,000
Ending Balance - Warrants outstanding, Number of Shares (in shares)	6,828,800	6,828,800
Warrants exercisable, Number of Shares (in shares)	6,659,840	6,659,840
Beginning Balance - Warrants outstanding, Weighted Average Exercise Price (in dollars per share)	$0.67	$0.61
Warrants Issued, Weighted Average Exercise Price (in dollars per share)	$0	$0
Warrants Exercised, Weighted Average Exercise Price (in dollars per share)	$0	$0.54
Warrants Expired, Weighted Average Exercise Price (in dollars per share)	$0	$0.84
Ending Balance - Warrants outstanding, Weighted Average Exercise Price (in dollars per share)	$0.67	$0.67
Warrants exercisable, Weighted Average Exercise Price (in dollars per share)	$0.67	$0.67
Warrants outstanding, Weighted Average Exercise Price Average Remaining Contractual Life (in year)	'8 months 1 day	'
Warrants exercisable, Weighted Average Exercise Price Average Remaining Contractual Life (in year)	'5 months 1 day	'

Share_Exchange_Agreement_Priva3

Share Exchange Agreement, Private Placements and Common Stock Warrants (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share Exchange Agreement Private Placement And Common Stock Warrants [Line Items]	'	'	'
Exercise Prices (in dollars per share)	$0.67	$0.67	$0.61
Warrants Outstanding	6,828,800	6,828,800	13,454,552
Warrants Exercisable	6,659,840	6,659,840	'
Exercise Price One [Member]	'	'	'
Share Exchange Agreement Private Placement And Common Stock Warrants [Line Items]	'	'	'
Exercise Prices (in dollars per share)	$0.50	'	'
Warrants Outstanding	2,253,800	'	'
Warrants Exercisable	2,084,840	'	'
Exercise Price Two [Member]	'	'	'
Share Exchange Agreement Private Placement And Common Stock Warrants [Line Items]	'	'	'
Exercise Prices (in dollars per share)	$0.75	'	'
Warrants Outstanding	4,575,000	'	'
Warrants Exercisable	4,575,000	'	'

Share_Exchange_Agreement_Priva4

Share Exchange Agreement, Private Placements and Common Stock Warrants (Details Textual) (USD $)

0 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

101 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

5 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

Jan. 31, 2010

Jun. 30, 2006

Oct. 31, 2005

Jun. 30, 2012

Sep. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2009

Dec. 31, 2013

Dec. 31, 2006

Dec. 31, 2012

Dec. 31, 2012

Jun. 30, 2006

Dec. 31, 2006

Jun. 30, 2011

Jul. 31, 2006

Jun. 30, 2006

Jul. 31, 2011

Jul. 27, 2012

Dec. 31, 2006

Dec. 31, 2007

Apr. 30, 2009

Mar. 31, 2009

Feb. 28, 2009

Apr. 30, 2009

Dec. 31, 2009

Nov. 30, 2009

Nov. 06, 2009

Jan. 31, 2010

Jan. 20, 2010

Feb. 28, 2010

Feb. 22, 2010

Dec. 31, 2009

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

31-May-12

Dec. 31, 2005

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2012

Dec. 31, 2012

Sep. 11, 2012

Sep. 11, 2012

Sep. 11, 2012

January 20, 2013 [Member]

February 22, 2013 [Member]

Private Placement [Member]

Private Placement [Member]

First Private Placement Issue [Member]

First Private Placement Issue [Member]

First Private Placement Issue [Member]

First Private Placement Issue [Member]

First Private Placement Issue [Member]

First Private Placement Issue [Member]

Second Private Placement Issue [Member]

Third Private Placement Issue [Member]

Third Private Placement Issue [Member]

Third Private Placement Issue [Member]

Third Private Placement Issue [Member]

Third Private Placement Issue [Member]

Fourth Private Placement Issue [Member]

Fourth Private Placement Issue [Member]

Fifth Private Placement Issue [Member]

Fifth Private Placement Issue [Member]

Sixth Private Placement Issue [Member]

Sixth Private Placement Issue [Member]

Pro Active Agreement [Member]

Exercise Price One [Member]

Exercise Price Two[Member]

Minimum [Member]

Maximum [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Warrant Type 1 [Member]

Warrant Type 1 [Member]

Warrant Type 1 [Member]

Warrant Type 2 [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Share Exchange Agreement Private Placement And Common Stock Warrants [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued To Founders (in shares)

'

19,021,786

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,021,786

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

'

'

$1,500

'

'

$0

$0

'

$1,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued To Founders, Prior Share Exchange Agreement (in shares)

'

'

1,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares outstanding (in shares)

'

25,000,832

'

'

'

41,583,097

41,583,097

'

41,583,097

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in connection with reverse merger transaction (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,005,177

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Acquisitions, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16.00%

'

'

'

'

'

'

'

'

'

Private Placement Fee

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in private placement, net of offering costs (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,581,351

1,973,869

'

'

'

'

'

'

'

'

1,420,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,575,000

2,420,000

999,995

3,555,220

'

'

'

'

'

'

'

'

'

Common Stock Units Issued In Private Placement (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

999,995

500,000

262,000

658,000

'

'

1,000,000

'

3,575,000

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Units, Issued In Private Placement, Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Each unit sold in the third private placement consisted of one share of the Companys common stock and a five-year warrant to purchase an additional share of the Companys common stock on a cashless exercise basis at an exercise price of $0.50 per common share.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued In Private Placement, Per Share Price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.33

$0.33

'

'

'

$0.65

'

'

'

'

'

$0.75

'

$0.75

'

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Share Units Issued In Private Placement, Per Share Price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.50

$0.50

$0.50

'

'

$0.50

'

$0.50

'

$0.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

526,590

657,299

'

'

'

650,000

250,000

131,000

329,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Private Placement Commission, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

'

'

'

10.00%

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Private Placement Commission, Non Accountable Fee, Percentage In Gross Proceeds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.00%

4.00%

'

'

'

4.00%

'

'

'

4.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Private Placement Commission, Warrants Issued, Exercise Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'five-year warrants

'five-year warrants

'

'

'

'five-year warrants

'

'

'

'five-year warrants

'

'three-year warrant

'

'three-year warrant

'

'three year-year warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Of Warrants Issued As Private Placement Commission, Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'(a) 10% of the number of shares sold in the private placement exercisable at $0.333 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.333 per share. A total of 189,762 warrants were issued.

'(a) 10% of the number of shares sold in the private placement exercisable at $0.333 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.333 per share. A total of 236,864 warrants were issued.

'

'

'

'(a) 10% of the number of shares sold in the private placement exercisable at $0.65 per share and (b) an additional 2% of the number of shares sold in the private placement also exercisable at $0.65 per share. Net cash proceeds to the Company were $531,320.

'

'

'

'(a) 10% of the number of shares sold in the third private placement exercisable at $0.50 per share and 10% of the number of shares issuable upon exercise of warrants issued in the third private placement exercisable at $0.50 per share; and (b) an additional 2% of the number of shares sold in the third private placement also exercisable at $0.50 per share and 2% of the number of shares issuable upon exercise of the warrants issued in the third private placement exercisable at $0.50 per share.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Private Placement Commission, Warrants Issued, Number (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

426,626

'

189,762

236,864

'

'

'

120,000

'

'

'

'

340,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Issuance Of Private Placement Net Of Offering Costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

446,433

522,939

'

'

'

531,320

214,800

112,460

269,790

'

'

500,000

'

1,787,500

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued In Private Placement, Exercise Price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.33

'

$0.33

$0.33

'

'

'

$0.65

'

'

'

'

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Closing Price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.50

'

$0.49

'

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercised Cashless Basis, Number (in shares)

'

'

'

'

'

'

273,752

'

'

'

'

'

'

'

152,874

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued, Cashless Exercise Of Warrants, Number (in shares)

'

'

'

'

'

'

141,955

'

'

'

'

'

'

'

100,929

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Extension, Stock Agreed For Issuance, Number (in shares)

'

'

'

'

'

'

273,752

'

'

'

'

'

'

'

'

'

'

'

273,752

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant extensions

'

'

'

'

'

0

1,139,592

'

1,339,431

'

'

'

'

'

'

'

'

199,839

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,139,592

'

'

'

'

Fair Value Of Warrant Extension, Per Share Price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.73

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Valuation Fair Value Assumption Number (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,082,000

'

'

1,000,000

'

'

'

'

'

Warrants Valuation, Fair Value Assumptions Share Price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.79

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.69

$0.84

$0.69

'

'

'

'

'

Warrants Valuation, Fair Value Assumptions Exercise Price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.33

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Valuation Fair Value Assumptions Stated Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.50

'

'

$0.75

'

'

'

'

'

Warrants Valuation Fair Value Assumptions Discounted Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.38

'

'

$0.56

'

'

'

'

'

Warrants Valuation, Fair Value Assumptions Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'157 years

'661 years

'157 years

'

'

'

'

'

Warrants Valuation, Fair Value Assumptions Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

308.80%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150.10%

'

'

150.10%

'

'

'

'

'

Warrants Valuation, Fair Value Assumptions Expected Dividend Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

0.00%

'

'

'

'

'

Warrants Valuation, Fair Value Assumptions Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.14%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.24%

'

'

0.24%

'

'

'

'

'

Warrants Issued During Period, Private Placement, Number (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,420,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent Warrants Included In Third Private Placement Issue, Number (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

170,400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advances under equity financing

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Advances Under Equity Financing

587,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Registration Rights Agreement, Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The agreement required the Company to file a registration statement within 45 days of the closing of the private placement and to have the registration statement declared effective within 120 days of the closing of the private placement.

'

'

'

'

'The registration rights agreement requires the Company to file a registration statement within 75 days of receipt of written demand from holders who represent at least 50% of the common shares issued pursuant to the second private placement, provided that no demand shall be made for less than 500,000 shares, and to use its best efforts to cause such registration statement to become and remain effective for the requisite period.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued In Private Placement Mentioned In Registration Rights Agreement Number

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,555,220

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liquidated Damages Payable, Monthly Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liquidated damages payable under registration rights agreement

'

'

'

'

'

74,000

74,000

'

74,000

74,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued During Period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares and Warrants Exercisable One (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares and Warrants Exercisable Per Share One (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares and Warrants Exercisable Two (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares and Warrants Exercisable Per Share Two (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares and Warrants Exercisable Three (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares and Warrants Exercisable Per Share Three (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Of Warrants Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

97,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Of Warrants Issued Per Share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.65

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Of Restricted Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Of Restricted Common Stock Per Share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.67

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

198,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash Basis Warrants Exercise Price Reduction Percentage

'

'

'

'

'

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Prices (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.33

$1.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum Proceeds Expected From Issuance Of Warrants

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,440

'

6,082,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercised At Discount Price Range

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.13

$0.19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from exercise of warrants

'

'

'

2,468,250

'

0

2,468,250

'

2,468,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant discount

'

'

'

'

$334,024

$0

$334,024

'

$334,024

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Warrants Exercisable Fair Market Value

'

'

'

'

'

'

$0.83

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Warrants Outstanding

'

'

'

'

'

168,960

'

'

168,960

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless Basis Warrants Exercise Price Increased Percentage

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless Exercise Price (in dollar per share)

'

'

'

'

'

'

$0.33

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increased Cashless Exercise Price

'

'

'

'

'

'

$0.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Common Stock To Be Issued Upon Conversion Of Warrants

'

'

'

'

'

'

5,080,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Common Stock To Be Issued Upon Conversion Of Warrants Issue One

'

'

'

'

'

'

'

'

'

'

505,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issue Price Issue One

'

'

'

'

'

'

'

'

'

'

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Common Stock To Be Issued Upon Conversion Of Warrants Issue Two

'

'

'

'

'

'

'

'

'

'

3,575,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issue Price Issue Two

'

'

'

'

'

'

'

'

'

'

$0.75

$0.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.22

'

'

Fair Value Assumptions, Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.65

$0.50

$0.75

Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'493 years

'526 years

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

148.40%

'

'

'

Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.29%

'

'

'

Stock Options and Warrants Exercisable Fair Market Value

'

'

'

'

'

$0.13

$0.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Money_Market_Funds_Fair_Value_1

Money Market Funds - Fair Value (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Money Market Funds Fair Value [Line Items]	'	'
Assets, Fair Value Disclosure, Recurring	$6,135	$6,134
Fair Value, Inputs, Level 1 [Member]	'	'
Money Market Funds Fair Value [Line Items]	'	'
Assets, Fair Value Disclosure, Recurring	6,135	6,134
Fair Value, Inputs, Level 2 [Member]	'	'
Money Market Funds Fair Value [Line Items]	'	'
Assets, Fair Value Disclosure, Recurring	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Money Market Funds Fair Value [Line Items]	'	'
Assets, Fair Value Disclosure, Recurring	$0	$0

Money_Market_Funds_Fair_Value_2

Money Market Funds - Fair Value (Details Textual) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Money Market Funds Fair Value [Line Items]	'	'
Money Market Funds, at Carrying Value	$6,135	$6,134

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)

1 Months Ended

12 Months Ended

101 Months Ended

12 Months Ended

101 Months Ended

12 Months Ended

101 Months Ended

12 Months Ended

Feb. 28, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Feb. 18, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

31-May-13

Dec. 01, 2012

21-May-12

Oct. 15, 2011

Apr. 15, 2011

Feb. 18, 2011

Oct. 15, 2010

Apr. 15, 2010

Apr. 07, 2010

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Sep. 21, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jan. 28, 2014

Jan. 28, 2014

Exercise Price One [Member]

Exercise Price Two [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Consulting Arrangements [Member]

Agreement With Theradex Systems [Member]

Agreement With Theradex Systems [Member]

Agreement With Theradex Systems [Member]

Agreement With Theradex Systems [Member]

NDA Consulting Corp [Member]

NDA Consulting Corp [Member]

NDA Consulting Corp [Member]

NDA Consulting Corp [Member]

NDA Consulting Corp [Member]

NDA Consulting Corp [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Dr. Von Hoff [Member]

June 24, 2014 [Member]

June 24, 2015 [Member]

June 24, 2016 [Member]

June 24, 2017 [Member]

June 24, Thereafter [Member]

Exercise Price One [Member]

Exercise Price Two [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Due to stockholder

'

$92,717

$92,717

$92,717

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Officers Compensation, Approved, Per Month

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Officers Compensation, Approved, Per Month, Effective Date Of Adoption

15-Mar-11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Officers' Compensation

'

60,000

60,000

167,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual Fee Payable, Clinical Trial

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

Annual Fee Payable, Clinical Trial, Installment Amount

'

'

'

'

'

'

'

'

'

'

'

12,500

12,500

12,500

12,500

'

12,500

12,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consultancy Fees Paid

'

'

'

'

'

'

'

10,417

21,875

75,000

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

'

'

'

'

'

'

'

'

Fees For Services Total

'

14,964

163,661

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,964

163,661

194,551

'

'

'

'

'

'

'

'

'

Stock Based Compensation Expense Relating To Directors Officers And Other Related Parties

'

119,250

1,017,004

3,598,461

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Clinical Cost Charged To Operations Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

278,721

'

'

'

'

'

'

'

'

'

'

'

Additional Annual Fee Payable Clinical Trial

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Expired, Weighted Average Exercise Price

'

$0

$0.84

'

'

$0.50

$0.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercisable

'

6,659,840

6,659,840

6,659,840

'

2,084,840

4,575,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,253,800

4,575,000

Stock Granted, Value, Share-based Compensation, Net of Forfeitures, Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

25,000

25,000

25,000

25,000

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.13

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	1 Months Ended	6 Months Ended	12 Months Ended
	31-May-11	Jun. 30, 2011	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Beginning Balance - Options outstanding - Number of Shares (in shares)	'	'	3,750,000	3,250,000
Granted - Number of Shares (in shares)	200,000	200,000	100,000	1,200,000
Exercised - Number of Shares (in shares)	'	'	0	-100,000
Expired - Number of Shares (in shares)	'	'	-700,000	-600,000
Ending Balance - Options outstanding - Number of Shares (in shares)	'	'	3,150,000	3,750,000
Options exercisable - Number of Shares (in shares)	'	'	3,000,000	3,512,500
Beginning Balance - Options outstanding - Weighted Average Exercise Price (in dollars per share)	'	'	$0.87	$0.88
Granted - Weighted Average Exercise Price (in dollars per share)	'	'	$0.13	$0.80
Exercised - Weighted Average Exercise Price (in dollars per share)	'	'	$0	$0.33
Expired - Weighted Average Exercise Price (in dollars per share)	'	'	$1.04	$0.89
Ending Balance - Options outstanding - Weighted Average Exercise Price (in dollars per share)	'	'	$0.82	$0.87
Options exercisable - Weighted Average Exercise Price (in dollars per share)	'	$0.98	$0.84	$0.88
Options outstanding - Weighted Average Remaining Contractual Life (in Years)	'	'	'2 years 7 months 13 days	'
Options exercisable - Weighted Average Remaining Contractual Life (in Years)	'	'	'2 years 6 months 7 days	'

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Prices (in dollars per share)	$0.82	$0.87	$0.88
Options Outstanding (in shares)	3,150,000	3,750,000	3,250,000
Options Exercisable (in shares)	3,000,000	3,512,500	'
Exercise Price One [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Prices (in dollars per share)	$0.13	'	'
Options Outstanding (in shares)	100,000	'	'
Options Exercisable (in shares)	0	'	'
Exercise Price Two [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Prices (in dollars per share)	$0.33	'	'
Options Outstanding (in shares)	200,000	'	'
Options Exercisable (in shares)	200,000	'	'
Exercise Price Three [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Prices (in dollars per share)	$0.50	'	'
Options Outstanding (in shares)	200,000	'	'
Options Exercisable (in shares)	200,000	'	'
Exercise Price Four [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Prices (in dollars per share)	$0.65	'	'
Options Outstanding (in shares)	700,000	'	'
Options Exercisable (in shares)	650,000	'	'
Exercise Price Five [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Prices (in dollars per share)	$0.98	'	'
Options Outstanding (in shares)	450,000	'	'
Options Exercisable (in shares)	450,000	'	'
Exercise Price Six [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Prices (in dollars per share)	$1	'	'
Options Outstanding (in shares)	1,500,000	'	'
Options Exercisable (in shares)	1,500,000	'	'

StockBased_Compensation_Detail2

Stock-Based Compensation (Details Textual) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

24 Months Ended

101 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

24 Months Ended

12 Months Ended

Oct. 15, 2009

Jan. 31, 2009

Jan. 31, 2008

Jun. 30, 2007

Feb. 05, 2007

Feb. 28, 2013

Aug. 31, 2011

31-May-11

Jun. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2008

Jun. 30, 2008

Dec. 31, 2013

Jan. 28, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2006

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Aug. 31, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Sep. 11, 2012

Feb. 04, 2012

Feb. 28, 2011

Jan. 31, 2008

Feb. 28, 2007

Aug. 31, 2009

Feb. 28, 2009

Dec. 31, 2012

Jan. 28, 2008

Sep. 30, 2012

Sep. 11, 2012

Sep. 30, 2007

Sep. 30, 2011

Oct. 15, 2009

Sep. 30, 2008

Sep. 30, 2007

Dec. 31, 2012

Dec. 31, 2009

Sep. 30, 2007

Sep. 12, 2007

Sep. 19, 2008

Sep. 30, 2007

Sep. 12, 2007

Dec. 31, 2007

Jun. 30, 2011

Jun. 30, 2006

Jun. 30, 2011

Jun. 30, 2006

Dec. 31, 2013

Dec. 31, 2012

Feb. 28, 2013

Jun. 30, 2006

Dec. 31, 2006

Jun. 30, 2006

Jul. 31, 2011

Jun. 30, 2011

Jun. 30, 2006

Dec. 31, 2013

Dec. 31, 2012

Oct. 05, 2011

Sep. 30, 2009

Sep. 30, 2007

Apr. 19, 2011

Sep. 12, 2008

Sep. 12, 2009

Oct. 31, 2008

Dec. 31, 2008

Oct. 07, 2010

Dec. 31, 2011

1-May-11

Subsequent Event [Member]

Subsequent Event [Member]

New Transactions [Member]

New Transactions [Member]

Transactions Requiring-Re Evaluation In Prior Periods [Member]

Transactions Requiring-Re Evaluation In Prior Periods [Member]

Dr Mullinix [Member]

Dr Mullinix [Member]

Dr Mullinix [Member]

Dr. Von Hoff [Member]

Dr. Von Hoff [Member]

Madajewicz [Member]

Dr. Royds [Member]

Dr. Royds [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Chem Master Agreement [Member]

Chem Master Agreement [Member]

Chem Master Agreement [Member]

Chem Master Agreement [Member]

Chem Master Agreement [Member]

Chem Master Agreement [Member]

Chem Master Agreement [Member]

Chem Master Agreement [Member]

Chem Master Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement With Francis Johnson [Member]

Consulting Agreement With Francis Johnson [Member]

Consulting Agreement With Francis Johnson [Member]

Mirador Agreement [Member]

Outside Director Stock Award Plan [Member]

Outside Director Stock Award Plan [Member]

Outside Director Stock Award Plan [Member]

Outside Director Stock Award Plan [Member]

Outside Director Stock Award Plan [Member]

Outside Director Stock Award Plan [Member]

Outside Director Stock Award Plan [Member]

Outside Director Additional Stock Award Plan [Member]

Outside Director Additional Stock Award Plan [Member]

Scientific Advisory Committee Members [Member]

Scientific Advisory Committee Members [Member]

Scientific Advisory Committee Members [Member]

Scientific Advisory Committee Members [Member]

Scientific Advisory Committee Members [Member]

Scientific Advisory Committee Members [Member]

Director Stock Award Plan [Member]

Director Stock Award Plan [Member]

Director Stock Award Plan [Member]

Director Stock Award Plan [Member]

Director Stock Award Plan [Member]

Director Stock Award Plan [Member]

Board Of Director Stock Award Plan [Member]

Board Of Director Stock Award Plan [Member]

Board Of Director Stock Award Plan [Member]

Board and Medical Director Of Theradex Systems, Inc [Member]

Board and Medical Director Of Theradex Systems, Inc [Member]

Subsequent Event [Member]

New Transactions [Member]

Transactions Requiring-Re Evaluation In Prior Periods [Member]

New Transactions [Member]

Transactions Requiring-Re Evaluation In Prior Periods [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures (in shares)

'

'

'

'

'

'

'

200,000

200,000

100,000

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,548

97,770

'

'

'

'

'

'

'

200,000

100,000

'

100,000

500,000

'

'

500,000

'

'

1,000,000

'

'

'

'

1,000,000

'

'

300,000

'

'

'

200,000

200,000

'

'

'

'

190,000

'

100,000

'

'

50,000

'

'

500,000

'

200,000

'

'

'

'

200,000

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

'

'

'

'

'

'

'

'

'

'2 years 6 months 7 days

'

'

'

'

'

'

'5 years

'5 years

'

'

'5 years

'

'

'

'

'

'

'

'

'4 years

'

'3 years 6 months

'

'

'

'

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'

'

'4 years

'4 years

'

'

'

'

'

'

'

'5 years

'5 years

'

'

'

'5 years

'

'5 years

'

'

'

'

'

'5 years

'

'5 years

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in dollars per share)

'

'

'

'

'

'

'

'

$0.98

$0.84

$0.88

'

'

$0.84

'

'

$0.13

$0.65

'

$0.25

'

'

$0.65

$0.13

'

'

'

'

$1

$1

$0.65

$0.98

$0.65

'

$0.48

'

$0.33

'

$0.33

'

$1.65

'

$1

'

'

'

'

'

'

$1

'

'

'

'

$0.33

'

'

$0.33

'

$0.33

'

'

$0.98

'

$0.33

$0.33

'

'

$0.33

'

'

$1

'

'

'

$0.33

'

'

'

'

'

$0.98

Share Based Compensation Arrangement By Share Based Payment Award Options Vested (in shares)

'

25,000

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

100,000

'

'

100,000

'

'

'

'

'

500,000

'

'

500,000

'

'

500,000

'

'

100,000

'

'

'

'

66,666

25,000

'

'

'

'

58,900

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

25,000

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value

'

'

'

'

'

'

'

'

$49,000

'

'

'

'

'

'

'

'

'

'

'

'

'

$118,000

$12,960

'

'

'

'

'

'

'

'

$293,450

'

'

'

$31,000

'

'

'

$96,000

'

$286,100

'

'

'

'

'

$325,000

$750,000

'

$945,000

'

'

$300,000

'

'

$62,000

'

$62,000

'

'

$196,000

'

'

'

'

'

'

'

'

'

'

'

'

'

$204,000

'

$0.50

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

$0.02

'

'

'

'

'

'

$0.59

'

'

'

'

'

'

'

'

'

$0.59

'

'

'

$0.31

'

'

'

'

'

$0.57

'

'

'

'

$0.95

$0.65

$0.75

'

'

'

$1

'

'

'

'

'

$0.31

'

'

'

$0.31

'

'

'

'

'

'

'

'

$1.02

'

'

'

'

'

'

$0.50

$0.98

'

Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Charged To Operations

375,000

'

75,000

'

'

'

'

'

'

'

'

'

41,334

'

'

134,420

'

'

'

'

'

58,690

31,790

125

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

465,000

'

'

'

'

210,410

'

'

'

'

'

'

'

'

'

'

20,666

48,530

98,134

'

'

'

'

'

'

'

3,357

-650

'

'

'

'

'

'

'

'

100,000

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)

'

'

'

'

'

100,000

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

15,015

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

Stock Issued Shares Cash Less Exercise (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,020

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Expirations In Period (in shares)

'

'

'

'

'

'

'

'

'

700,000

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

290,000

'

'

'

'

'

'

'

'

'

'

34,985

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Options Vested Ratably (in shares)

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from exercise of stock options

'

'

'

'

33,333

'

'

'

'

0

33,333

'

'

38,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

262.00%

262.00%

148.40%

128.40%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.51%

1.51%

0.78%

0.24%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum Shares For Granting Of Awards (in shares)

'

'

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting Fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40,000

'

'

'

'

Stock Issued During Period Per Share Restricted Stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Of Restricted Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

262,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Of Restricted Common Stock Per Share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Price Per Share Of Restricted Common Stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Price Per Share Of Restricted Common Stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent

'

'

'

'

'

'

'

'

'

$40,000

'

'

'

$40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Options and Warrants Exercisable Fair Market Value (in dollars per share)

'

'

'

'

'

'

'

'

'

$0.13

$0.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Options Vested

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Option Vested Year One

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Option Vested Year Two

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Option Vested Year Three

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_Taxes_Details

Income Taxes (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Taxes Expense Benefit [Line Items]	'	'
Start-up and organization costs	$56,000	$63,000
Research credits	95,000	68,000
Contingent liability	31,000	31,000
Net operating loss carryforwards	2,939,000	2,421,000
Total deferred tax assets	3,121,000	2,583,000
Valuation allowance	-3,121,000	-2,583,000
Net deferred tax assets	$0	$0

Income_Taxes_Details_1

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes Expense Benefit [Line Items]	'	'
U. S. federal statutory tax rate	-34.00%	-34.00%
Non-deductible stock-based compensation	2.90%	8.60%
Non-deductible fair value of warrant extensions	0.00%	10.80%
Non-deductible fair value of warrant discounts	0.00%	3.20%
Adjustment to deferred tax asset	-1.30%	-2.00%
Change in valuation allowance	32.40%	13.40%
Effective tax rate	0.00%	0.00%

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013
Income Taxes Expense Benefit [Line Items]	'
Operating Loss Carryforwards	$7,099,000
Operating Loss Carry forwards Expiration Period	'2032 years

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2006
Commitments And Contingencies [Line Items]	'	'	'
Research and development contracts	$40,385	'	'
Theradex work order agreement	1,746,463	'	'
Patent license agreement	150,000	'	'
Consulting Agreement	16,000	'	'
Liquidated damages payable under registration rights agreement	74,000	74,000	74,000
Due to stockholder	92,717	'	'
Total	2,119,565	'	'
Payments Due By 2014 [Member]	'	'	'
Commitments And Contingencies [Line Items]	'	'	'
Research and development contracts	40,385	'	'
Theradex work order agreement	1,346,463	'	'
Patent license agreement	30,000	'	'
Consulting Agreement	16,000	'	'
Liquidated damages payable under registration rights agreement	74,000	'	'
Due to stockholder	92,717	'	'
Total	1,599,565	'	'
Payments Due By 2015 [Member]	'	'	'
Commitments And Contingencies [Line Items]	'	'	'
Research and development contracts	0	'	'
Theradex work order agreement	400,000	'	'
Patent license agreement	30,000	'	'
Consulting Agreement	0	'	'
Liquidated damages payable under registration rights agreement	0	'	'
Due to stockholder	0	'	'
Total	430,000	'	'
Payments Due By 2016 [Member]	'	'	'
Commitments And Contingencies [Line Items]	'	'	'
Research and development contracts	0	'	'
Theradex work order agreement	0	'	'
Patent license agreement	30,000	'	'
Consulting Agreement	0	'	'
Liquidated damages payable under registration rights agreement	0	'	'
Due to stockholder	0	'	'
Total	30,000	'	'
Payments Due By 2017 [Member]	'	'	'
Commitments And Contingencies [Line Items]	'	'	'
Research and development contracts	0	'	'
Theradex work order agreement	0	'	'
Patent license agreement	30,000	'	'
Consulting Agreement	0	'	'
Liquidated damages payable under registration rights agreement	0	'	'
Due to stockholder	0	'	'
Total	30,000	'	'
Payments Due By 2018 [Member]	'	'	'
Commitments And Contingencies [Line Items]	'	'	'
Research and development contracts	0	'	'
Theradex work order agreement	0	'	'
Patent license agreement	30,000	'	'
Consulting Agreement	0	'	'
Liquidated damages payable under registration rights agreement	0	'	'
Due to stockholder	0	'	'
Total	$30,000	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)

0 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

101 Months Ended

12 Months Ended

Feb. 05, 2012

Oct. 01, 2011

Oct. 01, 2010

Mar. 05, 2009

Nov. 10, 2008

Oct. 01, 2008

Sep. 29, 2008

Sep. 19, 2008

Jun. 29, 2007

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2011

Sep. 30, 2009

Aug. 31, 2009

Jul. 06, 2006

Mar. 22, 2006

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Sep. 21, 2012

Dec. 31, 2013

Dec. 31, 2013

Dr. Von Hoff [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Agreement With Theradex Systems [Member]

Agreement With Theradex Systems [Member]

Agreement With Theradex Systems [Member]

Agreement With Theradex Systems [Member]

Agreement With Ascentage Pharma Group [Member]

Other Unrelated Vendor [Member]

Dr. Von Hoff [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Dr. Von Hoff [Member]

Dr. Von Hoff [Member]

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cooperative Research and Development Project Commitments, Amount

'

'

'

'

'

'

'

'

'

'

'

'

$200,000

$100,000

'

$200,000

'

'

'

'

'

'

'

'

'

'

'

'

Cooperative Research Commitments Due, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments To Fund Cooperative Research and Development

25,000

25,000

50,000

50,000

'

50,000

50,000

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

National Institute Of Health Patent License Agreement, Terms

'

'

'

'

'

'

'

'The PLA provided for an initial payment of $25,000 to the NIH within 60 days of September 19, 2008, and for a minimum annual royalty of $30,000 on January 1 of each calendar year following the year in which the CRADA is terminated.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patent License Agreement, Minimum Annual Royalty, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

'

'

'

'

'

'

'

'

'

'

Payments To National Institute Of Health Patent License Agreement Initial Payment

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and Development Contract, Estimated Cost, Various Clinical Studies

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

29,025

104,100

Research and Development Contract, Payments For Various Clinical Studies

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,415

75,325

Principal Cash Obligations and Commitments, Current

'

'

'

'

'

'

'

'

'

213,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual Fee Payable, Clinical Trial

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

Fees For Services Total

'

'

'

'

'

'

'

'

'

14,964

163,661

'

'

'

'

'

'

'

'

'

'

'

14,964

163,661

194,551

'

'

'

Clinical Cost Charged To Operations Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

278,721

'

'

'

'

'

Charges To Operations

'

'

'

'

'

'

'

'

'

7,275

24,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting Fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,000

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

4,000,000

'

100,000

'

'

'

'

'

'

Stock Options Vested

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

25,000

'

'

25,000

'

'

'

'

'

'

Stock Option Vested In Next Twelve Months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

Stock Option Vested In Year Two

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

Stock Option Vested In Year Three

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

$0.84

$0.88

$0.98

'

'

'

'

$0.13

'

'

$0.50

$0.13

$0.13

'

'

'

'

'

'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)

0 Months Ended

12 Months Ended

24 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Oct. 15, 2009

Jan. 31, 2008

Dec. 31, 2013

Jun. 30, 2008

Dec. 31, 2012

Jun. 30, 2011

Dec. 31, 2013

Dec. 31, 2013

Jan. 28, 2014

Dec. 31, 2013

Jan. 28, 2014

Jan. 28, 2014

Jan. 28, 2014

Jan. 28, 2014

Jan. 28, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 01, 2014

Jan. 31, 2014

Jan. 28, 2015

Jan. 28, 2014

Dec. 31, 2013

Exercise Price One [Member]

Exercise Price Two [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Dr Mullinix [Member]

Dr Mullinix [Member]

Dr Mullinix [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Exercise Price One [Member]

Exercise Price Two [Member]

Maximum [Member]

Minimum [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Feb 10, 2014 Warrants [Member]

Mar 2, 2014 Warrants [Member]

Apr 6, 2014 Warrants [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting Fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000

'

'

'

'

'

Consulting Fees One

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,500

'

'

'

Consulting Fees Two

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,500

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

78,617

'

'

'

'

'

'

'

'

596,400

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

'

'

$0.15

$0.02

'

'

'

'

$0.15

$0.04

'

'

'

'

'

'

'

'

$0.15

Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Charged To Operations

375,000

75,000

'

41,334

'

'

'

'

'

134,420

'

'

'

'

'

'

'

'

'

'

'

'

'

'

298,200

Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,748,800

$815,920

$312,880

$620,000

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price

'

'

$0.84

'

$0.88

$0.98

'

'

'

'

'

'

'

'

$0.50

'

'

'

'

'

'

'

'

'

$0.50

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

262.00%

'

'

'

'

'

262.00%

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

1.51%

'

'

'

'

'

1.51%

'

'

'

'

'

'

'

'

'

Exercise Price Reduction Percentage

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Price Before Reduction

'

'

'

'

'

'

'

'

'

'

'

'

$0.75

$0.50

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

'

'

'2 years 7 months 13 days

'

'

'

'

'

'

'77 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

2,000,000

'

Warrants Exercisable

'

'

6,659,840

'

6,659,840

'

2,084,840

4,575,000

'

'

2,253,800

4,575,000

'

'

'

'

'

'

'

'

'

'

'

'

'